

## Publikationen iTZ Ruhr 2020 bis 2018

### Publikationen Katholisches Klinikum Bochum

#### Klinik für Allgemein- und Viszeralchirurgie

Luu AM, Künzli B, Hoehn P, Munding J, **Lukas C, Uhl W**, Braumann  
Prognostic value and impact of cerebral metastases in pancreatic cancer. Acta Chir Belg.  
2020 Feb;120(1):30-34

Ueberberg S, ...**Uhl W**, ... Tannapfel A, Clark A, Meier  
Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2  
Diabetes, and Nondiabetic Patients.  
J Clin Endocrinol Metab. 2020 Aug 1;105

Radulova-Mauersberger O, ... **Uhl W**, Witzigmann H  
[Indications for Surgical and Interventional Therapy of Acute Pancreatitis].  
Zentralbl Chir. 2020 Aug;145(4):374-382

Herzog-Niescery J, Seipp HM, Bellgardt M, **Herzog T**, Belyaev O, **Uhl W**, Gude P, Weber  
TP, Vogelsang H  
Comparison of 3 Methods to Assess Occupational Sevoflurane Exposure in Abdominal  
Surgeons: A Single-Center Observational Pilot Study. Anesth Analg. 2020 Aug;131(2):537-  
543

Fietkau R, ... **Reinacher-Schick A**, ... **Uhl W**, Lubgan D  
R0 resection following chemo (radio)therapy improves survival of primary inoperable  
pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.  
Strahlenther Onkol. 2020 Sep 10

Weisner J, ... Tannapfel A, **Uhl W**, ... Siveke JT, Rauh D  
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with  
Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.  
Cancer Res. 2019 May 1;79(9):2367-2378

Fahlbusch T, Braumann C, **Uhl W**...  
[Treatment of abdominal tuberculosis : Background, diagnostics and treatment of a global  
problem].  
Chirurg. 2019 Oct;90(10):818-822

Berger AW, ... **Reinacher-Schick A, Uhl W**, ... Seufferlein T.  
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage  
Pancreatic Cancer.  
Theranostics. 2019 Feb 12;9(5):1280-1287

Wittel UA, ... **Uhl W**, ... **Reinacher-Schick A**, ... Golcher H

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.  
BMC Cancer. 2019 Oct 22;19(1):979

Petrova E, ... **Uhl W**, ... Wellner UF  
Risk stratification for postoperative pancreatic fistula using the pancreatic surgery registry StuDoQ|Pancreas of the German Society for General and Visceral Surgery.  
Pancreatology. 2019 Jan;19(1):17-25

Bolm L, ... **Uhl W**, ... Wellner UF  
The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Pancreas).  
Pancreatology. 2019 Oct;19(7):985-993

Luu AM, Hoehn P, Vogel SR, **Reinacher-Schick A**, Munding J, **Uhl W**, Braumann C  
Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visc Med. 2019 Dec;35(6):387-391

Uzunoglu FG, ... **Uhl W**, ... Bockhorn M  
Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort.  
Eur J Surg Oncol. 2019 May;45(5):793-799

Luu AM, Künzli B, Hoehn P, Munding J, Lukas C, **Uhl W**, **Braumann C**.  
Prognostic value and impact of cerebral metastases in pancreatic cancer.  
Acta Chir Belg. 2020 Feb;120(1):30-34

Luu AM, Braumann C, **Uhl W**, Janot-Matuschek M, Herzog T  
Does autologous fibrin sealant (vivostat<sup>®</sup>) reduce the incidence of postoperative pancreatic fistula after distal pancreatectomy? - a matched pairs analysis.  
Acta Chir Belg. 2019 Aug 30:1-7

Höhn P, Braumann C, Munding J, Tannapfel A, **Uhl W**, Künzli  
Outcome Determining Factors of Intraductal Papillary Neoplasm of the Biliary Tract (IPNB)-a Single Center Survey and Analysis of Current Literature.  
BMJ Gastrointest Cancer. 2019 Mar;50(1):160-169

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, **Uhl W**, Seufferlein T  
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.  
BMC Cancer. 2018;18(1): 1298

Luu AM, Herzog T, **Uhl W**, Belyaev O  
Feasibility evaluation of an action camera for video documentation in open abdominal surgery  
EUR SURG. 2018;50(2): 45-49

Aghalarov I, Herzog T, **Uhl W**, Belyaev O

A modified single-loop reconstruction after pancreaticoduodenectomy reduces severity of postoperative pancreatic fistula in high-risk patients.

HPB (Oxford). 2018;20(7): 676-683

Breuer TKG, Kampmann K, Wutzler A, Steinfort C, **Uhl W**, Schmidt WE, Meier JJ

[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy: Two case reports].

Internist (Berl). 2018;59(3): 282-287

Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, **Uhl W**, **Braumann C**

FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

J Gastrointest Oncol. 2018;9(2): E9-E12

Ivins N, Braumann C, Kirchhoff JB, **Waldemar U**, Jones NJ

Use of a gelling fibre dressing in complex surgical or chronic wounds: a case series.

J Wound Care. 2018;27(7): 444

Herzog-Niescery J, Vogelsang H, Gude P, Seipp HM, Bartz H, **Uhl W**, Weber TP, Bellgardt M  
The impact of the anesthetic conserving device on occupational exposure to isoflurane among intensive care healthcare professionals.

Minerva Anesthesiol. 2018;84(1): 25-32

Mayerle J, Kalthoff H, Kamlage B, Christiansen N, Schatz P, Fahlbusch T, Bethan B, Pellengahr SS, Krusekopf S, Chromik A, Klein F, Bahra M, Distler M, Pilarsky C, Grutzmann R, **Uhl W**, Lerch M

Differentiation of pancreatic cancer from chronic pancreatitis with a novel plasma-based targeted LC-MS/MS assay

Oncology research and treatment. 2018;41 1: 6-7

Wittel UA, Golcher H, Grutzmann R, Bechstein WO, Belyaev O, **Uhl W**, Ghadimi M, Hopt U, Pirkl A, Lubgan D, Hohenberger WM, Oettle H, Fietkau R

Reliability of determining the resectability of locally progressed pancreatic ductal adenocarcinomas - results from the CONKO-007 multicenter randomized controlled trial (EudraCT:2009-014476-21)

Künzli BM, Spohnholz J, Braumann C, Shrikhande SV, **Uhl W**

Clinical Impact of Iatrogenic Small Bowel Perforation Secondary to Laparoscopic Cholecystectomy: A Single-center Experience.

Surg Laparosc Endosc Percutan Tech. 2018;28(5): 309-313

Belyaev O, **Uhl W**

[Chronic Pancreatitis - An Updated Surgical Perspective].

Zentralbl Chir. 2018;143(6): 586-595

Horch RE, **Braumann C**, Dissemmond J, Lehner B, Hirche C, Woeste G, Wozniak G, Wetzel-Roth W, Willy C

[Use of Negative Pressure Wound Therapy with Instillation and Dwell Time for Wound Treatment - Results of an Expert Consensus Conference].  
Zentralbl Chir. 2018;143(6): 609-616

### **Klinik für Dermatologie, Venerologie und Allergologie**

Leiter U,... **Gambichler T**, Ugurel S.

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hemtological malignancy: a retrospective multicenter DeCOG study of 84 patients.

J Immunother Cancer. 2020 Oct

Sep Song L, ... **Gambichler T**, ... Becker JC.

The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells.

J Invest Dermatol. 2020

**Gambichler T**, Reuther J, Stücker M, Stranzenbach R, Torres-Reyes C, Schlottmann R, Schmidt WE, Hayajneh R, Sriram A, Becker JC.

SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion.

J Eur Acad Dermatol Venereol. 2020 Oct

Hessam S, **Gambichler T**, Skrygan M, Scholl L, Sand M, Meyer T, Stockfleth E, Bechara FG.

Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa.

J Eur Acad Dermatol Venereol. 2020 Sep

**Gambichler T**, Reuther J, Richards C, Doerler M.

Annular leukocytoclastic vasculitis in a patient with PR3-antineutrophil cytoplasmic antibody-positive ulcerative colitis.

Eur J Dermatol. 2020 Aug 1

**Gambichler T**, Susok L, Abu Rached N, Stücker M, Scheel C.

Dupilumab-induced psoriatic erythroderma with characteristic cytokine and antimicrobial peptide expression pattern in a patient with long standing atopic dermatitis.

Int J Dermatol. 2020 Sep

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, **Gambichler T**.

Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis: abridged Cochrane review.

Br J Dermatol. 2020 Jul 6

**Gambichler T**, Reuther J, Scheel CH, Becker JC.

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.

J Immunother Cancer. 2020 Jul

Lambert J, Marrel A, D'Angelo SP, Burgess MA, Chmielowski B, Fazio N, **Gambichler T**, Grob JJ, Lebbé C, Robert C, Russell J, Güzel G, Bharmal M.  
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. *Patient*. 2020 Aug;13(4):457-467

Hillen LM, Geybels MS, Spassova I, Becker JC, **Gambichler T**, Garmyn M, Zur Hausen A, van den Oord J, Winnepenninckx V.  
A digital mRNA expression signature to classify challenging Spitzoid melanocytic neoplasms. *FEBS Open Bio*. 2020 Jul;10(7):1326-1341

**Gambichler T**, Bünnemann H, Scheel CH, Bechara FG, Stücker M, Stockfleth E, Becker JC.  
Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma?  
*Clin Exp Dermatol*. 2020 May 18

**Gambichler T**, Steuke AK, Schmitz L, Stockfleth E, Becker JC.  
Altered hydroxymethylation in cutaneous squamous cell carcinoma and keratoacanthoma.  
*Br J Dermatol*. 2020 May 14

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, **Gambichler T**.  
Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.  
*Cochrane Database Syst Rev*. 2020 May 5;5(5):CD011941

**Gambichler T, Susok L**.  
PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia. *Immunotherapy*. 2020 May;12(7):451-457

**Gambichler T**, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L.  
Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.  
*Immunotherapy*. 2020 May;12(7):439-444

**Gambichler T**, Wrobel M, Koim S, Becker JC, Käfferlein HU, Brüning T, Lang K.  
A study on DNA hydroxymethylation in Kaposi sarcoma and cutaneous angiosarcoma.  
*J Eur Acad Dermatol Venereol*. 2020 Apr 11

**Gambichler T**, Koim S, ... Stockfleth E, Becker JC, Lang K.  
Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma.  
*J Immunother*. 2020 Jun;43(5):169-174  
Amaral T, ... **Gambichler T**... Zimmer L; \*German Dermatological Cooperative Oncology Group.  
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG\* study in 380 patients. *J Immunother Cancer*. 2020 Mar;8(1):e000333

**Gambichler T**, Ardabili S, Lang K, Dreißigacker M, Scheel C, Brand-Saberi B, Skrygan M, Stockfleth E, Käfferlein HU, Brüning T, Becker JC.  
Expression of Lefty predicts Merkel cell carcinoma-specific death.  
J Eur Acad Dermatol Venereol. 2020 Feb 5

Hessam S, **Gambichler T**, Höxtermann S, Skrygan M, Sand M, Garcovich S, Meyer T, Stockfleth E, Bechara FG.  
Frequency of circulating subpopulations of T-regulatory cells in patients with hidradenitis suppurativa.  
J Eur Acad Dermatol Venereol. 2020

**Gambichler T**, Doerler M, Nöpel-Dünnebacke S, Matschke J, Bräsen JH, Linke RP, **Susok L**.  
Haemorrhagic bullous lesions in cutaneous light-chain amyloidosis with smouldering myeloma.  
J Eur Acad Dermatol Venereol. 2020

**Gambichler T**, Schröter U, Höxtermann S, Susok L, Stockfleth E, Becker JC.  
Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.  
Br J Dermatol. 2020 May

**Gambichler T**, Susok L, Fels M, Schneider-Gold C, Hof Zum Berge F, Stockfleth E, Ayzenberg I  
Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female patient with melanoma.  
Br J Dermatol. 2020 Jan.

Jan Fan K, Gravemeyer J, Ritter C, Rasheed K, **Gambichler T**, Moens U, Shuda M, Schrama D, Becker JC.  
Large T Antigen-Induced Atonal Homolog 1 Is a Lineage-Dependency Oncogene in Merkel Cell Carcinoma.  
J Invest Dermatol. 2020

**Gambichler T**, Selke L, Rüdell I, Dreißigacker M, Stockfleth E, Schmitz L.  
Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma.  
J Eur Acad Dermatol Venereol. 2019 Dec;33(12):e446-

Kervarrec T, ... **Gambichler T**, ... Guyétant S.  
Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas.  
Mod Pathol. 2019 Apr;32(4):499-510

Kervarrec T, ... **Gambichler T**, ... Guyétant S.  
Morphologic and immunophenotypical features distinguishing Merkel cell polyomavirus-positive and negative Merkel cell carcinoma.  
Mod Pathol. 2019 Nov;32(11):1605-1616

Hessam S, **Gambichler T**, Höxtermann S, Skrygan M, Sand M, Garcovich S, Meyer T, Stockfleth E, Bechara FG.  
Frequency of circulating subpopulations of T-regulatory cells in patients with hidradenitis suppurativa.  
J Eur Acad Dermatol Venereol. 2020 Apr

Sand M, Bromba A, Sand D, **Gambichler T**, Hessam S, Becker JC, Stockfleth E, Meyer T, Bechara FG.  
Dicer Sequencing, Whole Genome Methylation Profiling, mRNA and smallRNA Sequencing Analysis in Basal Cell Carcinoma.  
Cell Physiol Biochem. 2019;53(5):760-773

**Gambichler T**, Salveridou K, Schmitz L, Käfferlein HU, Brüning T, Stockfleth E, Sand M, Lang K.  
Low Drosha protein expression in cutaneous T-cell lymphoma is associated with worse disease outcome.  
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1695-1699

Becker JC, Eigentler T, ... **Gambichler T**, ... Mauch C.  
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018.  
J Dtsch Dermatol Ges. 2019 May;17(5):562-576

**Gambichler T**, Chatzipantazi M, Schröter U, Stockfleth E, Gedik C.  
Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. Oncoimmunology.  
2019 Oct 21;8(12):e1677139

**Gambichler T**, Schröter U, Höxtermann S, **Susok L**, **Stockfleth E**, Becker JC  
Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.  
Br J Dermatol. 2020 May;182(5):1214-1220

Schmitz L, **Gambichler T**, Kost C, Gupta G, Stücker M, Stockfleth E, Dirschka T  
Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses.  
Br J Dermatol. 2019 Apr;180(4):916-921

**Gambichler T**, Doerler M, Kempka J, Bechara FG, Stücker M.  
Melanocytic soluble adenylyl cyclase protein expression around lentigo maligna and in contralateral control skin.  
Clin Exp Dermatol. 2019 Apr;44(3):300-303

**Gambichler T**, Selke L, Rüdell I, Dreißigacker M, Stockfleth E, Schmitz L.  
Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma.  
J Eur Acad Dermatol Venereol. 2019 Dec;33(12):e446-e447

**Gambichler T**, Mahjirian-Namari M, Reininghaus L, Schmitz L, Skrygan M, Schulze HJ, Schaller J, Girolomoni G.

Lysyl oxidase-like-2 mutations and reduced mRNA and protein expression in mid-dermal elastolysis.

Clin Exp Dermatol. 2019 Jan;44(1):47-51

**Gambichler T**, Schmitt K, Rüdell I, Dreibigacker M, Stockfleth E, Becker JC.

Decreased 5-hydroxymethylcytosine immunoreactivity in primary Merkel cell carcinoma is a strong predictor for disease-specific death.

Br J Dermatol. 2019 Aug;181(2):389-390

Schmitz L, Gupta G, Stücker M, Doerler M, **Gambichler T**, Welzel J, Szeimies RM, Bierhoff E, Stockfleth E, Dirschka T.

Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1092-1097

Schmitz L, ... **Gambichler T**, ... Dirschka T.

Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1535-1540

Rohner E, Bütikofer L, Franceschi S, **Brockmeyer N**, Egger M, Bohlius, et al J AIDS-Defining Cancer Project Work

Non-Hodgkin lymphoma risk in adults living with HIV across five continents.

AIDS. 2018;32(18): 2777-2786

AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord

Brockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, Fuchs T, Jakob T, Lange L, Pfutzner W, Mockenhaupt M, Ott H, Pfaar O, Ring J, Sachs B, Sitter H, Trautmann A, Treudler R, Wedi B, Worm M, Wurpts G, Zuberbier T, Merk HF

Guideline for the diagnosis of drug hypersensitivity reactions (vol 24, pg 94, 2015)

Allergo J. 2018;27(1): 40-42)

van der Zwan-Kralt P, de Graaf YGL, Vos LE, Uphoff-Meijerink EJ, Willemze R, Struijk L, Wannigen P, van der Meijden E, Plasmeijer EI, Wolterbeek R, Ocampo ACMA, Kanitakis J, **Stockfleth E**, Forschner T, et.al.

Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study.

Am J Transplant. 2018;18(5): 1220-1230

Bouwes Bavinck JN, H, EPI-HPV-UV-CA group

Moinzadeh P, Riemekasten G, Blank N, Henes J, Koetter I, Siegert E, Pfeiffer C, Zeidler G, Schmalzing M, Guenther C, **Susok L**, Worm M, Kreuter A, Sunderkoetter C, et. al.

SSC IN OLDER AGE: FREQUENT AND WITH A DIFFERENT PHENOTYPE. DATA OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS

Ann Rheum Dis. 2018;77 2: 1109-1109

Schmitz L, Hessam S, Scholl L, Reitenbach S, Segert MH, **Gambichler T**, **Stockfleth E**, Bechara FG



Histological findings after argon plasma coagulation: an ex-vivo study revealing a possible role in superficial ablative treatment of the skin.  
Arch Dermatol Res. 2018;310(2): 157-163 (Impact(2017)=2.148, Typ=Article; Journal Article; Evaluation Studies)

Lahner M, Ull C, Hagen M, von Schulze Pellengahr C, **Daniilidis K**, von Engelhardt LV, Lahner N, Teske W  
Cartilage Surgery in Overweight Patients: Clinical and MRI Results after the Autologous Matrix-Induced Chondrogenesis Procedure.  
Biomed Res Int. 2018;2018: 6363245

**Gambichler T**, Wolf P

Irradiance, as well as body site and timing of readings, is important in determining ultraviolet A minimal erythema dose: reply from the authors.  
Br J Dermatol. 2018;178(1): 298-299

Hessam S, Sand M, **Gambichler T**, Skrygan M, Rüdell I, **Bechara FG**

Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop.  
Br J Dermatol. 2018;178(3): 761-767

**Stockfleth E**, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T

Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp': reply from the authors.  
Br J Dermatol. 2018;178(3): 813-814

Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, **Bechara FG**, Cohen AD, Daham N, Davis M, Emtestam L, et.al.

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.  
Br J Dermatol. 2018;178(3): 715-721

**Gambichler T**, Segert MH, **Höxtermann S**, **Stockfleth E**, Doerler M

Absence of immunoglobulin heavy chain rearrangement in primary Merkel cell carcinomas.  
Clin Exp Dermatol. 2018;43(8): 947

Skov T, **Stockfleth E**, Szeimies RM, Berman B

Efficacy Endpoints in Clinical Trials in Actinic Keratosis.  
Dermatol Ther (Heidelb). 2018;8(3): 425-433

Hessam S, **Gambichler T**, Skrygan M, Sand M, Rüdell I, Scholl L, **Bechara FG**

Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.  
Eur J Dermatol. 2018;28(4): 449-456 (Impact(2017)=1.944, Typ=Article; Journal Article)

**Bechara F**, Horvath B, Jemec G, Podda M, Prens E, Zouboulis C, Geng Z, Capriles CR  
Adalimumab in conjunction with surgery in patients with moderate to severe Hidradenitis

Suppurativa: Study design and baseline results from a phase 4, double blind, randomized, placebo-controlled study  
Exp Dermatol. 2018;27 1: 14-14

Mehdizadeh A, Alavi A, Alhusayen R, Bauer B, **Bechara FG**, Bourcier M, Brassard A, Djamei V, Dutz J, George R, Ghias M, Gooderham M, Hamzavi I, Hoffman LK, Hou A, et.al  
Proceeding report of the Symposium on Hidradenitis Suppurativa Advances (SHSA).  
Exp Dermatol. 2018;27(1): 104-112

**Stockfleth E**, Bastian M

Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.

Expert Opin Drug Metab Toxicol. 2018;14(9): 911-918

Monge S, **Brockmeyer N**, Prieto L, Conejo P, Soriano-Arandes A, Battegay M, Kouyos R, Mussini C, Tookey P, et.al.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

HIV Med. 2018;19(1): 42-48 Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

Klingenberg RE, Esser S, **Brockmeyer NH**, Michalik C, Skaletz-Rorowski A, Potthoff A, Kompetenznetz HIV/AIDS [Profile of Kaposi sarcoma patients in the competence network HIV/AIDS].

Hautarzt. 2018;69(2): 143-148

Knupfer J, Reich-Schupke S, **Stücker M**

Conservative management of varicosis and postthrombotic syndrome].

Hautarzt. 2018;69(5): 413-424

Reich-Schupke S, Mohren E, **Stücker M**

[Survey on the diagnostics and therapy of patients with lymphedema and lipedema].

Hautarzt. 2018;69(6): 471-477

Scholl L, Hessam S, Reitenbach S, **Bechara FG**

[Surgical treatment options for hidradenitis suppurativa/acne inversa].

Hautarzt. 2018;69(2): 149-161

Brook G, **Brockmeyer N**, van de Laar T, Schellberg S, Winter AJ

2017 European guideline for the screening, prevention and initial management of hepatitis B and C infections in sexual health settings.

Int J STD AIDS. 2018;29(10): 949-967

Engelberg WL, Dörler M, **Stücker M**, Reich-Schupke S

Impact of Gram-negative bacteria on the treatment of venous leg ulcers.

Int Wound J. 2018;15(6): 958-965

Schmitz L, Hessam S, Scholl L, Reitenbach S, Segert MH, **Gambichler T**, **Stockfleth E**, **Bechara FG**

Argon plasma coagulation of actinic keratoses imaged by optical coherence tomography: An in vivo study indicating a possible lesion-directed treatment.  
J Biophotonics. 2018;11(10): e201800075

Leiter UM, Stadler R, Mauch C, Hohenberger W, **Brockmeyer N**, Berking C  
Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.  
J Clin Oncol. 2018;36 S(15)

Scholl L, Hessam S, Bergmann U, **Bechara FG**  
Surgical Treatment of Sinus Tracts and Fistulas in Perianal Hidradenitis Suppurativa.  
J Cutan Med Surg. 2018;22(2): 239-241

### **Brockmeyer N**

The Way to the Future, or  
J Dtsch Dermatol Ges. 2018;16 3: 6-6

**Gambichler T**, Salveridou K, Schmitz L, Susok L, Kafferlein HU, Bruning T, Stockfleth E, Sand M, Lang K  
The Protein Expression of Drosha in cutaneous T-cell Lymphoma is associated with clinical Outcome Parameters: preliminary Results  
J Dtsch Dermatol Ges. 2018;16 6: 30-31

### **Gambichler T, Stucker M, Schmitz L, Susok L, Stockfleth E, Dorler M**

Melanocytic Expression of the soluble Adenylyl Cyclase in Lentiginous melanoma and in contralateral Control Skin  
J Dtsch Dermatol Ges. 2018;16 6: 45-46

Gravemeyer J, Lange A, Wulbeck C, Melior A, Spassova I, **Gambichler T**, Ritter C, Becker J  
Epigenetic Profiling distinguishes variant MCC-Cell Lines from classical MCC-Cell Lines and SCC-Cell Lines  
J Dtsch Dermatol Ges. 2018;16 6: 23-24

Gross GE, Werner RN, Becker JC, **Brockmeyer NH**, Esser S, Hampl M, Hommel S, Jongen J, Mestel DS, Meyer T, Petry KU, Plettenberg A, Püschel K, Schneede P, Schöfer H, Sotlar K, Weyandt G, Wieland U, Wiese-Posselt M, Nast A  
S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version).  
J Dtsch Dermatol Ges. 2018;16(2): 242-255 (Impact(2017)=2.743, Typ=Article; Journal Article)

### Schmitz L, Oster-Schmidt C, **Stockfleth E**

Nichtmelanozytäre Hauttumoren - von der aktinischen Keratose bis zum Plattenepithelkarzinom.  
J Dtsch Dermatol Ges. 2018;16(8): 1002-1014

Schmitz L, Novak B, Hoeh AK, **Gambichler T**, von Dobbeler C, Szeimies RM, Stockfleth E, Dirschka T

Somatic Mutations in the Kinetochores Gene KNSTRN are associated with basal proliferating actinic Keratosis and cutaneous Squamous Cell Carcinoma  
J Dtsch Dermatol Ges. 2018;16 6: 25-26

Schmitz L, Oster-Schmidt C, **Stockfleth E**  
Nonmelanoma skin cancer - from actinic keratosis to cutaneous squamous cell carcinoma.  
J Dtsch Dermatol Ges. 2018;16(8): 1002-1013

Schmitz L, **Stücker M, Gambichler T, Stockfleth E**, Dirschka T Histological intralesional heterogeneity of actinic keratoses relates to field cancerization.  
J Dtsch Dermatol Ges. 2018;16(10): 1211-1217

Schu M, Jonas B, Schluter C, Potthoff A, Wach J, Kayser A, Syllwasschy J, Chmielorz M, Skaletz-Rorowski A, Brockmeyer N  
Walk In Ruhr - Added Value of integrative Care: Selected Results from two Years of scientific Support  
J Dtsch Dermatol Ges. 2018;16 3(1): 7-8

Skaletz-Rorowski A, Potthoff A, Wach J, Kayser A, Kasper A, **Brockmeyer NH**  
The PreYoungGo Study: Sexually transmitted Infections and Sexual Behavior in Adolescents and young Adults in the Ruhr Area  
J Dtsch Dermatol Ges. 2018;16 3: 42-43

Skaletz-Rorowski A, Potthoff A, Wach J, Kayser A, Kasper A, **Brockmeyer NH**  
Point-of-care Diagnosis of sexually transmitted Infections: The PreYoungGo Study  
J Dtsch Dermatol Ges. 2018;16 3: 24-25

**Gambichler T**, Brown V, Steuke AK, Schmitz L, **Stockfleth E, Susok L**  
Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.  
J Eur Acad Dermatol Venereol. 2018;32(6): 972-977 (Impact(2017)=4.287, Typ=Article; Journal Article)

**Gambichler T**, Rüdell I, Hessam S, Bechara FG, Stockfleth E, Schmitz L  
Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery.  
J Eur Acad Dermatol Venereol. 2018;32(9): 1485-1491 (Impact(2017)=4.287, Typ=Article; Journal Article)

Schmitz L, **Gambichler T**, Gupta G, Stücker M, Stockfleth E, Szeimies RM, Dirschka T  
Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment.  
J Eur Acad Dermatol Venereol. 2018;32(5): 745-751 (Journal Article)

Schmitz L, **Stockfleth E**  
Actinic keratoses seldom occur alone.  
J Eur Acad Dermatol Venereol. 2018;32(4): 513

Schmitz L, **Gambichler T**, Gupta G, Stücker M, Dirschka T

Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma.

J Eur Acad Dermatol Venereol. 2018;32(5): 752-756

Ulrich M, Reinhold U, Falqués M, Rodriguez Azeredo R, **Stockfleth E**

Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double-blind, vehicle-controlled trial.

J Eur Acad Dermatol Venereol. 2018;32(3): 390-396

**Gambichler T, Stockfleth E, Susok L**

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.

J Immunother Cancer. 2018;6(1): 113

D'Angelo SP, Russell J, Lebbé C, Chmielowski B, **Gambichler T**, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL  
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

JAMA Oncol. 2018;4(9): e180077

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D, BRIM8 Investigators, Cinat G, Fein LE, Brown M, Vantuchova Y, Putnik K, Dreno B, Dutriaux C, Grob JJ, Joly P, Lacour JP, Meyer N, Mortier L, Thomas L, Fluck M, **Gambichler T**, Hassel J, Hauschild A, et.al.

Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Brunner G, **Gambichler T**, Reinhold U, Schulze HJ, Tsagoudis K, Bierhoff E, Sulberg H, Borowski M, Hinke A, **Stockfleth E**

A prognostic gene expression profile complements staging of thin fatal melanomas and melanomas with known sentinel lymph node status

Oncology research and treatment. 2018;41 1: 162-162

Schmitz L, von Dobbeler C, Gupta G, **Gambichler T**, Szeimies RM, Morton CA, Dirschka T  
Photodynamic therapy leads to significant improvement of actinic keratosis area and severity index (AKASI).

Photodiagnosis Photodyn Ther. 2018;21: 66-70 (Impact(2017)=2.895, Typ=Article; Journal Article)

Schmitz L, Gupta G, Segert MH, Kost R, Sternberg J, **Gambichler T, Stockfleth E**, Dirschka T

Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.

Skin Pharmacol Physiol. 2018;31(4): 206-211 (Impact(2017)=1.974, Typ=Article; Journal Article)

## Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie

Völter C, Schirmer C, Hinsen D, Roeber M, **Dazert S**, Bilda K  
Therapist-Guided Telerehabilitation for Adult Cochlear Implant Users: Developmental and Feasibility Study. JMIR Rehabil Assist Technol. 2020 May 28;7(1):e15843

Stöver T, **Dazert S**, ... Zenk J  
[Effects of the SARS-CoV-2 pandemic on the otorhinolaryngology university hospitals in the field of medical care]. Laryngorhinootologie. 2020 Oct;99(10):694-706

Völter C, Schirmer C, Stöckmann C, **Dazert S**.  
[Computer-based auditory training for hearing rehabilitation of adult cochlear implant users]. HNO. 2020 Nov;68(11):817-827

Thomas JP, van Ackeren K, **Dazert S**, Todt I, Prescher A, Voelter C  
Transmastoid implantability of an active transcutaneous bone conduction implant in adults with regard to the underlying pathology: a radiological simulation study. Acta Otolaryngol. 2018;138(6): 530-536

Dombrowski T, Wrobel C, **Dazert S**, Volkenstein S  
Flipped classroom frameworks improve efficacy in undergraduate practical courses - a quasi-randomized pilot study in otorhinolaryngology. BMC Med Educ. 2018;18(1): 294

Völter C, Götze L, **Dazert S**, Falkenstein M, Thomas JP  
Can cochlear implantation improve neurocognition in the aging population? Clin Interv Aging. 2018;13: 701-712

Thomas JP, Drewermann S, Voelter C, **Dazert S**  
Prognostic factors regarding the hearing outcome in severe to profound sudden sensorineural hearing loss treated by tympanotomy and sealing of labyrinthine windows after ineffective systemic corticosteroid application. Eur Arch Otorhinolaryngol. 2018;275(7): 1749-1758

Gude P, Rieckert C, Bissantz N, Weber TP, Vogelsang H, **Dazert S**, Thomas JP  
[Need of analgetics in children aged 2-12 years after tonsil surgery]. Laryngorhinootologie. 2018;97(7): 465-473

Thomas JP, Neumann A, van Ackeren K, Dombrowski T, **Dazert S**  
[Techniques of stapedotomy]. Laryngorhinootologie. 2018;97(4): 236-237

Völter C, Götze L, Falkenstein M, **Dazert S**, Thomas JP  
[Computer based neurocognitive testing in audiology]. Laryngorhinootologie. 2018;97(4): 246-254

## Fachbereich Hämatologie, Onkologie und Palliativmedizin

**Noepel-Duenebacke S**, Juetter H, Feder IS, Kluxen L, Basara N, Hiller W, Herzog T, Klaassen-Mielke R, Mueller L, Senkal M, Engel L, Teschendorf C, Trenn G, Verdoodt B, Wolters H, Uhl W, **Reinacher-Schick A**, Tannapfel A. High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus. *Z Gastroenterol.* 2020 Jun;58(6):533-541. doi: 10.1055/a-1156-4433. Epub 2020 Jun 16. PMID: 32544965 English.

S.S. Lueong, A. Herbst, S. Liffers, N. Bielefeld, P.A. Horn, A. Tannapfel, **A. Reinacher-Schick**, A. Hinke, S. Hegewisch-Becker, F.T. Kolligs and J.T. Siveke, Serial circulating tumor DNA mutational status in patients with KRAS-mutant metastatic colorectal cancer from the phase 3 AIO KRK0207 trial, *Clinical Chemistry Article* Doi: 10.1093/clinchem/hvaa223, accepted for publication

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, **Reinacher-Schick A**, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators . Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. *Ann Oncol.* 2019 Dec 1;30(12):1959-1968. (IF: 14.196)

Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S., Ettrich T, Kanzler S°, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, **Reinacher-Schick AC**, Geissler M. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). *J Clin Oncol.* 2019 Dec 10;37(35):3401-3411. (IF: 26.303)

Wittel UA, Lubgan D, Ghadimi M, Belyaev O, Uhl W, Bechstein WO, Grützmann R, Hohenberger WM, Schmid A, Jacobasch L, Croner RS, **Reinacher-Schick A**, Hopt UT, Pirkl A, Oettle H, Fietkau R, Golcher H. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. *BMC Cancer.* 2019 Oct 22;19(1):979, (IF: 3.288)

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, **Reinacher-Schick A**, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* 2019 Jun 2. (IF: 70,670)

Haltaufderheide J, Wäscher S, Bertlich B, Vollmann J, **Reinacher-Schick, A.**, Schildmann J. "I need to know what makes somebody tick ...": Challenges and Strategies of Implementing Shared Decision-Making in Individualized Oncology. *Oncologist.* 2019 Apr;24(4):555-562. (IF: 5,252)

Tannapfel, A, **Reinacher-Schick, A**  
Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?

Visc Med 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8.  
PMID: 31312643 (IF: 1,989)

Tannapfel A, **Reinacher-Schick A**, Hacker U, Lorenzen S, Möhler M, Vogel A.  
Immunotherapy: New Options in Gastrointestinal Cancers?  
Visc Med. 2019 Mar;35(1):47-51. doi: 10.1159/000497293. Epub 2019 Feb 14. (IF: 1,989)  
PMID: 31312650

Berger AW, Schwerdel D, **Reinacher-Schick A**, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T.  
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.  
Theranostics. 2019 Feb 12;9(5):1280-1287 (IF: 8,063)

Pitarokoili K, Höffken N, Lönneker N, Fisse AL, Trampe N, Gold R, **Reinacher-Schick A**, Yoon MS.  
Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy.  
J Neuroimaging. 2019 Jan;29(1):133-139. (IF: 2.080)

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, **Reinacher-Schick A**, Uhl W, Seufferlein T.  
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.  
BMC Cancer. 2018 Dec 29;18(1):1298. (IF: 3,288)

Noepel-Duenebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, **Reinacher-Schick A**.  
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.  
Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. (IF: 3,176)

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Jütte H, Hegewisch-Becker S, Arnold D, **Reinacher-Schick A**.  
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.  
Front Oncol. 2018 Nov 8;8:474 (IF: 4,137)

Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, **Reinacher-Schick A**, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran S, Lange T, Dietrich G, Tannapfel A, Arnold D  
Impact of primary tumor location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.



Eur J Cancer. 2018 Sep;101:105-113 (IF: 6,680)

Luu AM, Herzog T, Hoehn P, **Reinacher-Schick A**, Munding J, Uhl W, Braumann C.  
FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

J Gastrointest Oncol. 2018 Apr;9(2):E9-E12. (IF: 1,66)

Ettrich TJ, Ebert M, Lorenzen S, Moehler M, Vogel A, Witkowski L, Seufferlein T, **Reinacher-Schick A**.

ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].

Z Gastroenterol. 2018 Apr;56(4):384-397. (IF: 1.236)

Salloch S, Otte IC, **Reinacher-Schick A**, Vollmann J.

Ärztliche Perspektiven auf die Bedeutung von Patientenpräferenzen und die Rolle Angehöriger bei der evidenzbasierten Entscheidungsfindung - eine qualitative Interviewstudie aus der Onkologie.

Z Evid Fortbild Qual Gesundhwes. 2018 Apr;131-132:46-52 (IF: 0,27)

Salloch S, Otte I, **Reinacher-Schick A**, Vollmann J.

What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study.

J Eval Clin Pract. 2018 Feb;24(1):180-186. (IF: 1.536)

mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109)

Ann Oncol. 2018;29 5: - (Impact(2017)=13.926, Typ=Meeting Abstract)

Geissler M, Klingler T, Riera-Knorrenschild J, Tannapfel A, Seufferlein T, Held S, Florschütz A, Kanzler S, Heinemann V, **Reinacher-Schick A**, Martens U

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, **Reinacher-Schick A**, Uhl W, Seufferlein T

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.

BMC Cancer. 2018;18(1): 1298 (Impact(2017)=3.288, Typ=Article; Journal Article)

Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, **Reinacher-Schick A**, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Kruger S, Westphalen CB, Held S, Heinemann V, Boeck S

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Eur J Cancer. 2018;94: 95-103 (Impact(2017)=7.191, Typ=Article; Proceedings Paper; Journal Article; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't)

Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, **Reinacher-Schick A**

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.

Clin Colorectal Cancer. 2018;17(4): e733-e739 (Impact(2017)=3.861, Typ=Article; Journal Article)

Hegewisch-Becker S, **Nöpel-Dünnebacke S**, Hinke A, Graeven U, **Reinacher-Schick A**, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.

Eur J Cancer. 2018;101: 105-113 (Impact(2017)=7.191, Typ=Article; Journal Article)

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Jütte H, Hegewisch-Becker S, Arnold D, **Reinacher-Schick A**

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients- Analysis of the Phase III AIO KRK-0207 Trial.

Front Oncol. 2018;8: 474 (Impact(2017)=4.416, Typ=Article; Journal Article)

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, Holdt LM, Den Winkel MO, Heinemann V, Stieber P, Graeven U, **Reinacher-Schick A**, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT

Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer (vol 140, pg 2134, 2017)

Int J Cancer. 2018;142(3): E1-E1 (Impact(2017)=7.36, Typ=Correction)

Schroeder C, Back C, Koc Ü, Strassburger-Krogias K, **Reinacher-Schick A**, Gold R, Haghikia A

Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis.

Clin Neurol Neurosurg. 2018;172: 24-26 (Impact(2017)=1.736, Typ=Article; Journal Article)

Siveke JT, Lueong S, Hinke A, Herbst A, Tannapfel A, **Reinacher-Schick AC**

Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial.

J Clin Oncol. 2018;36 S(15): - (Impact(2017)=26.303, Typ=Meeting Abstract)

Salloch S, Otte I, **Reinacher-Schick A**, Vollmann J What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study.

J Eval Clin Pract. 2018;24(1): 180-186 (Impact(2017)=1.483, Typ=Article; Journal Article)

Luu AM, Herzog T, Hoehn P, **Reinacher-Schick A**, Munding J, Uhl W, Braumann C FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

J Gastrointest Oncol. 2018;9(2): E9-E12 (Impact: liegt nicht vor, Typ=Article; Journal Article)

Geissler M, Klingler T, Tannapfel A, Riera-Knorrenschild J, Held S, Greeve J, Wessendorf S, Seufferlein T, Kanzler S, Heinemann V, **Reinacher-Schick A**, Martens U  
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): an update of the randomized phase II VOLFI trial of the AIO (AIO-KRK0109)  
Oncology research and treatment. 2018;41 4: 120-120 (Impact(2017)=1.494, Typ=Meeting Abstract)

Salloch S, Otte IC, **Reinacher-Schick A**, Vollmann J  
[Physician perspectives on the impact of patient preferences and the role of next-of-kin of patients in evidence-based decision-making: A qualitative interview study from oncology].  
Z Evid Fortbild Qual Gesundhwes. 2018;131-132: 46-52 (Impact: liegt nicht vor, Typ=Article; Journal Article; English Abstract)

Ettrich TJ, Ebert M, Lorenzen S, Moehler M, Vogel A, Witkowski L, Seufferlein T, **Reinacher-Schick A**  
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].  
Z Gastroenterol. 2018;56(4): 384-397 (Impact(2017)=1.612, Typ=Article; Journal Article; English Abstract)

#### Klinik für Allgemeine Innere Medizin - Medizinische Klinik I

Marso SP, **Nauck MA**, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators  
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).  
Am J Cardiol. 2018;121(12): 1467-1470 (Impact(2017)=3.171, Typ=Article; Journal Article)

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, **Nauck MA**, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA, LEADER Publication Committee on behalf of the LEADER Trial Investigators  
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.  
Circulation. 2018;137(20): 2179-2183 (Impact(2017)=18.88, Typ=Letter; Letter)

Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, **Nauck M**, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL  
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.  
Circulation. 2018;138(15): 1605-1607 (Impact(2017)=18.88, Typ=Letter; Letter)

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, **Nauck MA**, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP  
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Circulation. 2018;138(25): 2884-2894 (Impact(2017)=18.88, Typ=Article; Journal Article)

**Nauck MA**, Tornøe K, Rasmussen S, Treppendahl MB, Marso SP, LEADER Publication Committee on behalf of the LEADER Trial Investigators  
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.

Diab Vasc Dis Res. 2018;15(5): 465-468 (Impact(2017)=3.34, Typ=Article; Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't)

**Nauck MA**, Jensen TJ, Rosenkilde C, Calanna S, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.

Diabetes Care. 2018;41(8): 1663-1671 (Impact(2017)=13.397, Typ=Article; Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural)

**Nauck MA, Meier JJ**

Incretin hormones: Their role in health and disease.

Diabetes Obes Metab. 2018;20 Suppl 1: 5-21 (Impact(2017)=5.98, Typ=Review; Journal Article; Review)

Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, **Meier JJ**

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Diabetes Obes Metab. 2018;20(12): 2821-2829 (Impact(2017)=5.98, Typ=Article; Journal Article)

Zinman B, **Nauck MA**, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators

Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Diabetes Ther. 2018;9(6): 2383-2392 (Impact(2017)=2.224, Typ=Article; Journal Article)

Landgraf R, Kellerer M, Aberle J, Fach EM, Gallwitz B, Hamann A, Joost HG, Klein H, Muller-Wieland D, **Nauck MA**, Reuter HM, Schreiber S, Siegel E

Type 2 Diabetes Treatment

Diabetes und Stoffwechsel. 2018;13 2: S144-S165 (Impact(2017)=0.868, Typ=Guideline)

Dungan KM, Aroda VR, Knop FK, Leiter LA, Lausvig NL, Lindbergh S, Schwensen JF, **Meier JJ**

More subjects achieved composite reductions of  $\geq 1\%$  HbA(1c),  $\geq 5\%$  body weight and  $\geq 5$  mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials

Diabetologia. 2018;61 1: S359-S360 (Impact(2017)=6.023, Typ=Meeting Abstract)

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, **Nauck MA**, Pratley RE, Rea R, Saraiva J, Rasmussen S, Tornøe K, von Scholten B, Buse J, LEADER Publication Comm , LEADER Trial Investigators

Effect of liraglutide on cardiovascular outcomes in elderly patients in the LEADER trial  
Diabetologia. 2018;61 1: S368-S369 (Impact(2017)=6.023, Typ=Meeting Abstract)

Husain M, Bain SC, Mann JFE, **Nauck MA**, Poulter N, Baeres FMM, Goldman B, Thomsen AB, Marso S, LE

ADER Publication Comm , LEADER Trial Investigators Arrhythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

Diabetologia. 2018;61 1: S563-S564 (Impact(2017)=6.023, Typ=Meeting Abstract)

Leiter LA, Verma S, Mazer C, Bain SC, Buse J, Marso S, **Nauck MA**, Zinman B, Bosch-Traberg H, Frimer-Larsen H, Michelsen MM, Bhatt DL, LEADER Publication Comm , LEADER Trial Investigators

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

Diabetologia. 2018;61 1: S356-S357 (Impact(2017)=6.023, Typ=Meeting Abstract)

Lingvay I, de la Rosa R, Marre M, **Nauck M**, Woo V, Hansen T, Larsen JR, Yildirim E, Wilding J

Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs exenatide and dulaglutide in type 2 diabetes

Diabetologia. 2018;61 1: S375-S376 (Impact(2017)=6.023, Typ=Meeting Abstract)

**Nauck MA**, Saevereid HA, Ghorbani MLM, Kreiner E, Buse J

Effects of liraglutide versus placebo on gallbladder events: results from the LEADER trial

Diabetologia. 2018;61 1: S352-S352 (Impact(2017)=6.023, Typ=Meeting Abstract)

Saevereid HA, Husain M, Bain SC, Mann JFE, **Nauck MA**, Poulter N, Goldman B, Thomsen AB, Marso S, LEADER Publication Comm , LEADER Trial Investigators

Effect of liraglutide on cardiovascular outcomes in patients with or without prior heart failure history in LEADER

Diabetologia. 2018;61 1: S564-S565 (Impact(2017)=6.023, Typ=Meeting Abstract)

Tack C, Jacob S, Desouza C, Bain SC, **Nauck MA**, Petrie J, Poulter NR, Pratley RE, Stegmann HBK, Bosch-Traberg H, Startseva E, Zinman B, LEADER Publication Comm , LEADER Trial Investigators

Liraglutide effects in insulin-treated patients in LEADER

Diabetologia. 2018;61 1: S563-S563 (Impact(2017)=6.023, Typ=Meeting Abstract)

Trahair LG, **Nauck MA**, Wu T, Buttfield MDM, Stevens JE, Hatzinikolas S, Rayner CK, Meier J, Horowitz M, Jones KL

Measurement of gastric emptying using scintigraphy and a C-13-octanoic acid breath test with Wagner-Nelson analysis in type 2 diabetes

Diabetologia. 2018;61 1: S338-S339 (Impact(2017)=6.023, Typ=Meeting Abstract)

Verma S, Bain SC, Idorn T, Rasmussen S, Orsted DD, **Nauck MA**, LEADER Publication Comm , LEADER Trial Investigators

The cardiovascular benefits associated with liraglutide in the LEADER trial are sustained when analysing both first and recurrent MACE

Diabetologia. 2018;61 1: S540-S541 (Impact(2017)=6.023, Typ=Meeting Abstract)

Zinman B, Verma S, Bhatt DL, Bain SC, Mann J, **Nauck MA**, Pratley RE, Michelsen MM, Fries TM, Rasmussen S, Leiter LA, LEADER Publication Comm , LEADER Trial Investigators  
Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial

Diabetologia. 2018;61 1: S555-S556 (Impact(2017)=6.023, Typ=Meeting Abstract)

**Nauck M**, Araki A, Hehnke U, Plat A, Clark D, Khunti K

Risk of hypoglycaemia in people aged  $\geq 65$  years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.

Int J Clin Pract. 2018;72(10): e13240 (Impact(2017)=2, Typ=Article; Journal Article; Review; Meta-Analysis)

Frias JP, **Nauck MA**, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Lancet. 2018;392(10160): 2180-2193 (Impact(2017)=53.254, Typ=Article; Journal Article)

Institut für Diagnostische und Interventionelle Radiologie und Nuklearmedizin & Klinik für Strahlentherapie und Radioonkologie

Lutz T, Mönnings P, Ayzenberg I, **Lukas C**

Twig-like Middle Cerebral Artery: a Seldom Vessel Anomaly of Important Relevance.

Clin Neuroradiol. 2018;28(3): 441-443 (Impact(2017)=2.79, Typ=Editorial Material; Letter)

Duscha A, Hasse S, Berg J, Schneider R, **Lukas C**, Linker RA, Gold R, Haghikia A

Long term propionic acid supplementation leads to modulation of T effector cell balance/function and a decrease in annual relapse rate

Mult Scler. 2018;24 2: 398-399 (Impact(2017)=5.28, Typ=Meeting Abstract)

Huss A, Otto M, Tackenberg B, Stangel M, Aktas O, Meuth S, Gross CC, Bayas A, Wildemann B, Lussi F, Seipelt M, Putz M, Antony G, Weber F, Uhr M, Bischof F, Ruprecht K, Buck D, Retzlaff N, Zettl UK, Haghikia A, **Lukas C**, Hartung HP, Bergh FT, Warnke C  
Zipp Prospective multicenter validation of CSF protein biomarkers in patients with CIS and early MS

Mult Scler. 2018;24 2: 656-657 (Impact(2017)=5.28, Typ=Meeting Abstract)

Kruczek P, Bellenberg B, Lutz T, Schneider R, Ahlborn C, Gold R, Koster O, **Lukas C**

Developmental venous anomalies are more common in patients with multiple sclerosis & clinically isolated syndrome: co-incidence or clinically relevant?

Mult Scler. 2018;24 2: 817-817 (Impact(2017)=5.28, Typ=Meeting Abstract)

**Lukas C**, Prados F, Valsasina P, Parmar K, Brouwer I, Bellenberg B, Rovira A, Chard D, Kappos L, Rocca MA, Filippi M, Ciccarelli O, Barkhof F, Vrenken H

Quantification of spinal cord atrophy in MS: which software, which vertebral level, spinal cord or brain MRI? A multi-centric, longitudinal comparison of three different volumetric approaches.

Mult Scler. 2018;24 2: 88-90 (Impact(2017)=5.28, Typ=Meeting Abstract)

Middelkoop S, Weeda MM, Steenwijk MD, Daams M, Amiri H, Brouwer I, Killestein J, Uitdehaag BMJ, Dekker I, **Lukas C**, Bellenberg B, Barkhof F, Pouwels PJW, Vrenken H  
High reproducibility and robustness to lesions, but large software and scanner effects for mean upper cervical cord area (MUCCA) measurement in MS

Mult Scler. 2018;24 2: 853-854 (Impact(2017)=5.28, Typ=Meeting Abstract)

Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira A, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Biseco A, Gass A, Eisele P, **Lukas C**, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Comi G, Filippi M  
Cranio-caudal patterns of cervical cord atrophy progression in MS according to disease phenotype and clinical worsening: a multicenter study.

Mult Scler. 2018;24 2: 102-103 (Impact(2017)=5.28, Typ=Meeting Abstract)

Schiffmann I, Freund M, Engels K, Weierstall R, Rahn A, Backhus I, **Lukas C**, Chard D, Scheiderbauer J, Stellmann JP, Heesen C  
Understanding magnetic resonance imaging in multiple sclerosis (UMIMS): effect of an interactive online education tool on emotions, attitude and knowledge in people with multiple sclerosis

Mult Scler. 2018;24 2: 522-522 (Impact(2017)=5.28, Typ=Meeting Abstract)

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, **Lukas C**, Wattjes MP, Barkhof F, MAGNIMS Study Group

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Neurology. 2018;91(3): e249-e257 (Impact(2017)=7.609, Typ=Article; Journal Article)

Spicher C, Schneider R, Mönnings P, Schneider-Gold C, Kallenberg D, Cevik B, **Lukas C**, Gold R, Krogias C

Mechanical thrombectomy in a young stroke patient with Duchenne muscular dystrophy.

Ther Adv Neurol Disord. 2018;11: 1756286418759188 (Impact(2017)=4.75, Typ=Article; Journal Article)

## Publikationen Universitätsklinikum Knappschafts Krankenhaus (KKH)

Wiemann G, Pertz M, Kowalski T, Seidel S, **Schlegel U**, Thoma P. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work? J Neurooncol. 2020;doi: 10.1007/s11060-020-03587-5. Online ahead of print.

Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, **Schlegel U**, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous System Lymphoma using targeted mass spectrometry. Cancers (Basel) 2020;12: EE1732.doi:

Pertz M, Popkirov S, **Schlegel U**, Thoma P. Research on cognitive and sociocognitive functions in patients with brain tumors: a bibliometric analysis and visualization of the scientific landscape. *Neurol Sci* 2020;Epub Feb 2020

Pertz M, Okoniewski A, **Schlegel U**, Thoma P. Impairment of sociocognitive functions in patients with brain tumours. *Neuroscience and Biobehavioral Reviews* 2020;108: 370–392

Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, **Schroers R**, **Baraniskin A**, Pels H, Martus P, **Schlegel U**. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. *Neurol. Res. Pract.* 2019;1:17

Seidel S, **Schlegel U**. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. *Expert Rev Anticancer Ther.* 2019;19: 909 - 915

Weller J, Tzaridis T, Mack F, Steinbach JP, **Schlegel U**, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2019;20: 1444 - 1453

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, **Schlegel U**, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. *J Neurooncol.* 2019;144: 501 - 509

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westpfahl M, Krex D, Schackert G, Tonn JC, **Schlegel U**, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. *Acta Neuropathol Commun.* 2019;7: 59

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, **Schlegel U**, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyenbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczny P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA 09): a randomized, open-label, phase 3 trial. *Lancet* 2019;393: 678 – 688

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, **Schmiegel W**, **Pohl M**, Stoehlmacher J, Folprecht G, Probst S, Prasnikař N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, ... Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced,



resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.  
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1.  
Impact Factor: 60,392

**Baraniskin A**, Buchberger B, Pox C, Graeven U, Holch JW, **Schmiegel W**, Heinemann V.  
Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.  
Eur J Cancer. 2019 Jan;106:37-44. doi: 10.1016/j.ejca.2018.10.009.  
Impact Factor: 7,275

Blanco Belver A, Aach M, **Schmiegel W**, Schildhauer TA, Meindl R, Brechmann T.  
Similar Adenoma Detection Rates in Colonoscopic Procedures of Patients with Spinal Cord Injury Compared to Controls.  
Dig Dis Sci. 2020 Apr;65(4):1197-1205. doi: 10.1007/s10620-019-05814-0.  
Impact Factor: 2,751

Brechmann T, Günther K, Neid M, Tannapfel A, **Schmiegel W**.  
Phenotype of histologically suspected drug-induced colitis; results of a comparative, retrospective cohort study.  
Scand J Gastroenterol. 2019 Jul;54(7):855-862. doi: 10.1080/00365521.2019.1630674.  
Impact Factor: 2,130

Brechmann T, Günther K, Neid M, **Schmiegel W**, Tannapfel A.  
Triggers of histologically suspected drug-induced colitis.  
World J Gastroenterol. 2019 Feb 28;25(8):967-979. doi: 10.3748/wjg.v25.i8.967.  
Impact Factor: 3,665

Dominguez-Valentin M, ... **Schmiegel W**, **Vangala D**, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therikildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslin G, Mecklin JP, Nielsen M, Møller P.  
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.  
Genet Med. 2020 Jan;22(1):15-25. doi: 10.1038/s41436-019-0596-9.  
Impact Factor: 8,904

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, **Schmiegel W**, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group.  
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.  
J Clin Oncol. 2019 Dec 1;37(34):3212-3222. doi: 10.1200/JCO.19.00308.  
Impact Factor: 32,956

Gottlieb A, **Canbay A**.  
Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.  
Cells. 2019 Oct 30;8(11):1358. doi: 10.3390/cells8111358.  
Impact Factor: 4,366

Hüneburg R, Aretz S, Büttner R, Daum S, Engel C, Fechner G, Habermann JK, Heling D, Hoffmann K, Holinski-Feder E, Kloor M, von Knebel-Döberitz M, Loeffler M, Möslein G, Perne C, Redler S, Rieß O, **Schmiegel** W, Seufferlein T, Siebers-Renelt U, Steinke-Lange V, Tecklenburg J, **Vangala** D, Vilz T, Weitz J, Wiedenmann B, Strassburg CP, Nattermann J. [Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients].

Z Gastroenterol. 2019 Nov;57(11):1309-1320. doi: 10.1055/a-1008-9827.

Impact Factor: 1,338

Hüttmann A, ... Brink I, **Schroers** R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nüchel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0.

Impact Factor: 2,904

Ladigan S, Mika T, Figge A, May AM, **Schmiegel** W, **Schroers** R, **Baraniskin** A.

Acute myeloid leukemia with central diabetes insipidus.

Blood Cells Mol Dis. 2019 May;76:45-52. doi: 10.1016/j.bcmd.2019.01.005.

Impact Factor: 2,460

Mika T, Ladigan S, Schork K, Turewicz M, Eisenacher M, **Schmiegel** W, **Schroers** R, **Baraniskin** A.

Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML.

Blood Cells Mol Dis. 2019 Jul;77:103-108. doi: 10.1016/j.bcmd.2019.04.008.

Impact Factor: 2,460

Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, **Schroers** R.

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.

Front Med (Lausanne). 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295.

Impact Factor: 3,9

Mika T, **Baraniskin** A, Ladigan S, Wulf G, Dierks S, Haase D, Schork K, Turewicz M, Eisenacher M, **Schmiegel** W, **Schroers** R, Klein-Scory S.

Digital droplet PCR-based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation.

Int J Lab Hematol. 2019 Oct;41(5):615-621. doi: 10.1111/ijlh.13073.

Impact Factor: 2,141

Moehler M, ... Ott K, Quante M, Röcken C, Schlattmann P, **Schmiegel** WH, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S.

S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL.

Z Gastroenterol. 2019 Dec;57(12):1517-1632. doi: 10.1055/a-1018-2516.

Impact Factor: 1,338

Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, **Schmiegel** W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T.

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029.  
Impact Factor: 7,275

Ortmann O, Torode J, **Schmiegel** W, Thomssen C, Hakama M, Basu P, Ringborg U, Helbig U; participants of the ERTM.  
Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany.  
J Cancer Res Clin Oncol. 2020 Jul;146(7):1813-1818. doi: 10.1007/s00432-020-03209-7.  
Impact Factor: 3,656

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, **Schroers** R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.  
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.  
Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.  
Impact Factor: 17,543

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, **Schroers** R, Greil R, Grieshammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.  
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with *FLT3*-ITD.  
Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453.  
Impact Factor: 17,543

Seppälä TT, ... Vasen H, Morak M, Steinke-Lange V, Engel C, Rahner N, **Schmiegel** W, **Vangala** D, Thomas H, Green K, Laloo F, Crosbie EJ, Hill J, Capella G, Pineda M, Navarro M, Blanco I, Ten Broeke S, Nielsen M, Ljungmann K, Nakken S, Lindor N, Frayling I, Hovig E, Sunde L, Kloor M, Mecklin JP, Kalager M, Møller P.  
Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report.  
Hered Cancer Clin Pract. 2019 Feb 28;17:8. doi: 10.1186/s13053-019-0106-8.  
Impact Factor: 2,237

Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Maghnouj A, Müller MP, **Pohl** M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D.  
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in *KRAS*-Mutant Pancreatic and Colorectal Cancer.  
Cancer Res. 2019 May 1;79(9):2367-2378. doi: 10.1158/0008-5472.CAN-18-2861.  
Impact Factor: 9,727

Beier D, ... Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, **Schlegel** U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortman RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medullablastoma (NOA-07). Neuro Oncol. 2018;20: 400 - 410

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, **Schlegel** U, Sabel M, Ronellenfisch MW, Uhl M, Grau S,

Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018;20: 975 - 985

**Schlegel U**, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? *Curr Opin Neurol*. 2018;31: 733 - 739

Von Baumgarten L, Illerhaus G, Korfel A, **Schlegel U**, Deckert M, Dreyling M. The diagnosis and treatment of Primary CNS Lymphoma. *Dtsch. Ärzteblatt* 2018;115: 419 - 426

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, **Schlegel U**, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex d, Belka C, Vatter H, Proeschold M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. *J Cancer Clin Oncol*. 2018;144: 1581 - 1589

**Baraniskin A**, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, **Schlegel U**, **Schmiegel W**, Hahn S, **Schroers R**. Micro-RNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. *J Neurooncol*. 2018;137: 463 – 468

Althoff P, **Schmiegel W**, Lang G, Nicolas V, Brechmann T.  
Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease.  
*Dig Dis Sci*. 2018 Oct 1. doi: 10.1007/s10620-018-5303-1. [Epub ahead of print]  
Impact Factor: 2,550  
Affiliation BGH

**Baraniskin A**, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U, **Schmiegel W**, Hahn S, **Schroers R**.  
MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.  
*J Neurooncol*. 2018 Jan 11. doi: 10.1007/s11060-018-2749-0. [Epub ahead of print]  
Impact Factor: 3,060

Engel C, ...Schackert HK, **Schmiegel W**, Schulmann K, Steinke-Lange V, Strassburg CP, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel W, Zachariae S, Mecklin JP, Loeffler M; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group, and the Finnish Lynch Syndrome Registry.  
No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies.  
*Gastroenterology*. 2018 Jul 29. pii: S0016-5085(18)34818-2. doi: 10.1053/j.gastro.2018.07.030. [Epub ahead of print]  
Impact Factor: 16,716

Kayser K, Degenhardt F, Holzapfel S, Horpaopan S, Peters S, Spier I, Morak M, **Vangala D**, Rahner N, von Knebel-Doeberitz M, Schackert HK, Engel C, Büttner R, Wijnen J, Doerks T, Bork P, Moebus S, Herms S, Fischer S, Hoffmann P, Aretz S, Steinke-Lange V.  
Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes.  
*Int J Cancer*. 2018 Dec 1;143(11):2800-2813. doi: 10.1002/ijc.31725.  
Impact Factor: 5,145

Klein-Scory S, Maslova M, **Pohl M**, Eilert-Micus C, **Schroers R**, **Schmiegel W**, **Baraniskin A**.

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. *Transl Oncol.* 2018 Jan 19;11(2):213-220. doi: 10.1016/j.tranon.2017.12.010. [Epub ahead of print]  
Impact Factor: 3,071

Rösch T, Altenhofen L, Kretschmann J, Hagen B, Brenner H, Pox C, **Schmiegel W**, Theilmeyer A, Aschenbeck J, Tannapfel A, von Stillfried D, Zimmermann-Fraedrich K, Wegscheider K.  
Risk of Malignancy in Adenomas Detected During Screening Colonoscopy. *Clin Gastroenterol Hepatol.* 2018 Jun 11. pii: S1542-3565(18)30596-2. doi: 10.1016/j.cgh.2018.05.043. [Epub ahead of print]  
Impact Factor: 7,896

Vogl TJ, Pereira PL, Helmberger T, Schreyer AG, **Schmiegel W**, Fischer S, Herzog C. [Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention]. *Rofo.* 2018 Sep 26. doi: 10.1055/a-0750-1762. [Epub ahead of print] German. No abstract available.  
Kein Impact Factor

Vogl TJ, Pereira PL, Schreyer AG, **Schmiegel W**, Fischer S, Herzog C. Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention. *Rofo.* 2018 Sep 24. doi: 10.1055/a-0721-1947. [Epub ahead of print] English, German.  
Kein Impact Factor

**Vangala DB**, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, Güller U, Castells A, Carneiro F, Hammel P, Ducreux M, van Laethem JL, Matysiak-Budnik T, **Schmiegel W**. Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. *European Journal of Cancer*, 2018 November;104:91-103. <https://doi.org/10.1016/j.ejca.2018.09.004>  
Impact Factor: 7,275

## Publikationsliste

### Marien Hospital Herne – Universitätsklinikum der Ruhr-Universität Bochum

#### Urologische Klinik

Tully KH, Moschini M, von Rundstedt FE, Aziz A, Kluth LA, Necchi A, Rink M, Hendricksen K, Sargos P, Vetterlein MW, Seiler R, Poyet C, Krajewski W, Fajkovic H, Shariat SF, Xylinas E, **Rogmann F**. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. *Urol Oncol.* 2020 Nov;38(11):851.e19-851.e25. doi: 10.1016/j.urolonc.2020.06.034. Epub 2020 Jul 29. PMID: 32739227

Köhler CU, Walter M, Lang K, Plöttner S, Rogmann F, **Noldus J**, Tannapfel A, Tam YC, Käfferlein HU, Brüning T.

In-Vitro Identification and In-Vivo Confirmation of DNA Methylation Biomarkers for Urothelial Cancer.

Biomedicines. 2020 Jul 22;8(8):233. doi: 10.3390/biomedicines8080233. PMID: 32707764 Free PMC article.

Gild P, Vetterlein MW, Seiler R, Necchi A, Hendricksen K, Mertens LS, **Roghmann F**, Landenberg NV, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, D'Andrea D, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn BW, Noon AP, Roupret M, Shariat SF, Fisch M, Xylinas E, Rink M.

The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.

Surg Oncol. 2020 Sep;34:312-317. doi: 10.1016/j.suronc.2020.06.006. Epub 2020 Jun 30. PMID: 32891350

Tully KH, Bahlburg H, Berg S, Hanske J, von Landenberg N, **Noldus J**, Palisaar RJ, Roghmann F, Brock M. Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guideline-recommended Magnetic Resonance Imaging-based Risk Stratification in Men with Suspected Prostate Cancer.

Eur Urol Focus. 2020 Oct 6:S2405-4569(20)30273-X. doi: 10.1016/j.euf.2020.09.014. Online ahead of print. PMID: 33036953

Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, **Noldus J**, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Ivanyi P; (German Network Of Kidney Cancer).

Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.

Clin Genitourin Cancer. 2020 Jul 9:S1558-7673(20)30149-X. doi: 10.1016/j.clgc.2020.07.002. Online ahead of print. PMID: 32778505

Reicherz A, Maas V, Wenzel P, Dahlkamp L, Palisaar J, von Bodman C, **Noldus J**, Bach P. Transient stent placement versus tubeless procedure after ureteroscopy retrograde surgery stone extraction (Fast Track Stent study 2): A randomized prospective evaluation.

Int J Urol. 2020 Sep;27(9):749-754. doi: 10.1111/iju.14291. Epub 2020 Jul 6. PMID: 32974894

Săftoiu A, Gilja OH, Sidhu PS, Dietrich CF, Cantisani V, Amy D, Bachmann-Nielsen M, Bob F, Bojunga J, **Brock M**, Calliada F, Clevert DA, Correias JM, D'Onofrio M, Ewertsen C, Farrokh A, Fodor D, Fusaroli P, Havre RF, Hocke M, Ignee A, Jenssen C, Klauser AS, Kollmann C, Radzina M, Ramnarine KV, Sconfienza LM, Solomon C, Sporea I, Ștefănescu H, Tanter M, Vilmann P.

The EFSUMB Guidelines and Recommendations for the Clinical Practice of Elastography in Non-Hepatic Applications: Update 2018.

Ultraschall Med. 2019 Aug;40(4):425-453. doi: 10.1055/a-0838-9937. Epub 2019 Jun 25. PMID: 31238377 Free article. English.

Barr RG, Cosgrove D, **Brock M**, Cantisani V, Correas JM, Postema AW, Salomon G, Tsutsumi M, Xu HX, Dietrich CF.

WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography: Part 5. Prostate.

Ultrasound Med Biol. 2017 Jan;43(1):27-48. doi:

10.1016/j.ultrasmedbio.2016.06.020. Epub 2016 Aug 25. PMID: 27567060 Review.

Kowalski C, Roth R, Carl G, Feick G, Oesterle A, Hinkel A, Steiner T, **Brock M**, Björn Kaftan, Rainer Borowitz, Niko Zantl, Axel Heidenreich, Andreas Neisius, Christopher Darr, Christian Bolenz, Burkhard Beyer, Jesco Pfitzenmaier, Bernhard Brehmer, Jan Fichtner, Björn Haben, Wesselmann S, Dieng S

A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences

J Patient Rep Outcomes. 2020 Jul 13;4(1):56. doi: 10.1186/s41687-020-00224-7.

PMID: 32661594 PMCID: PMC7359206 DOI: 10.1186/s41687-020-00224-7

Tully KH, Cole AP, Krimphove MJ, Friedlander DF, Mossanen M, Herzog P, **Noldus J**, Sonpavde GP, Trinh QD.

Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?

Urology. 2020 Aug 14:S0090-4295(20)30983-3. doi: 10.1016/j.urology.2020.08.004.

Online ahead of print. PMID: 32805294

Reese SW, **Tully KH**, Nabi J, Paciotti M, Chou WH, Trinh QD.

Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades.

Eur Urol Oncol. 2020 Jul 11:S2588-9311(20)30089-4. doi:

10.1016/j.euo.2020.06.011. Online ahead of print. PMID: 32665140

Huynh MJ, Wang Y, Chang SL, **Tully KH**, Chung BI, Wright JL, Mossanen M.

The cost of obesity in radical cystectomy.

Urol Oncol. 2020 Jun 30:S1078-1439(20)30218-0. doi:

10.1016/j.urolonc.2020.05.014. Online ahead of print. PMID: 32620482

Tully KH, Roghmann F, **Noldus J**, Chen X, Häuser L, Kibel AS, Sonpavde GP, Mossanen M, Trinh QD.

Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

Clin Genitourin Cancer. 2020 Mar 31:S1558-7673(20)30075-6. doi:

10.1016/j.clgc.2020.03.013. Online ahead of print. PMID: 32335060

Berg S, Tully KH, Sahraoui A, Tan WS, Krimphove MJ, Marchese M, Lipsitz SR, **Noldus J**, Trinh QD.

Inequity in selective referral to high-volume hospitals for genitourinary malignancies.

Urol Oncol. 2020 Jun;38(6):582-589. doi: 10.1016/j.urolonc.2020.02.013. Epub 2020

Mar 23. PMID: 32217041

Witjes JA, ... Rink M, **Roghmann F**, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A,

Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Zigeuner R, Horwich A. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol. 2020 Jul;78(1):e48-e50. doi: 10.1016/j.eururo.2020.03.017. Epub 2020 May 21. PMID: 32446863 No abstract available.

Afferi L, Zamboni S, Karnes RJ, **Roghmann F**, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez-Maestro M, Martínez-Piñeiro L, Aziz A, Shariat SF, Abufaraj M, Xylinas E, Moschini M; The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. World J Urol. 2020 Apr 30. doi: 10.1007/s00345-020-03205-z. Online ahead of print. PMID: 32356226

Carando R, Pradere B, Afferi L, Marra G, Aziz A, **Roghmann F**, Krajewski W, Di Bona C, Alvarez-Maestro M, Pagliarulo V, Xylinas E, Moschini M. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. Prog Urol. 2020 May;30(6):322-331. doi: 10.1016/j.purol.2020.03.005. Epub 2020 Apr 9. PMID: 32279953

Wessels F, Lenhart M, Kowalewski KF, Braun V, Terboven T, **Roghmann F**, Michel MS, Honeck P, Kriegmair MC. Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols. World J Urol. 2020 Mar 2. doi: 10.1007/s00345-020-03133-y. Online ahead of print. PMID: 32124020

Krimphove MJ, Reese S, Chen X, Marchese M, Cone E, **Tully KH**, Paciotti M, Kibel AS, Melnitchouk N, Kluth LA, Dasgupta P, Trinh QD. Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. J Surg Oncol. 2020 Mar;121(3):578-583. doi: 10.1002/jso.25832. Epub 2020 Jan 8. PMID: 31916588

Friedlander DF, Krimphove MJ, Cole AP, **Tully KH**, Lipsitz SR, Kibel AS, Kilbridge KL, Trinh QD. Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun;27(6):1929-1936. doi: 10.1245/s10434-019-08110-3. Epub 2019 Dec 17. PMID: 31848818

Reese SW, **Tully KH**, Nabi J, Paciotti M, Chou WH, Trinh QD. Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades.



Eur Urol Oncol. 2020 Jul 11:S2588-9311(20)30089-4. doi: 10.1016/j.euo.2020.06.011. Online ahead of print.PMID: 32665140  
The cost of obesity in radical cystectomy.

Huynh MJ, Wang Y, Chang SL, **Tully KH**, Chung BI, Wright JL, Mossanen M. Urol Oncol. 2020 Jun 30:S1078-1439(20)30218-0. doi: 10.1016/j.urolonc.2020.05.014. Online ahead of print.PMID: 32620482

Roth R, Dieng S, Oesterle A, Feick G, Carl G, Hinkel A, Steiner T, Kaftan BT, Kunath F, Hadaschik B, Oostdam SJ, **Palisaar RJ**, Koralewski M, Beyer B, Haben B, Tsaour I, Wesselmann S, Kowalski C.

Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment.

World J Urol. 2020 Feb 10. doi: 10.1007/s00345-020-03097-z. Online ahead of print.PMID: 32040715

Kowalski C, Roth R, Carl G, Feick G, Oesterle A, Hinkel A, Steiner T, **Brock M**, Kaftan B, Borowitz R, Zantl N, Heidenreich A, Neisius A, Darr C, Bolenz C, Beyer B, Pfitzenmaier J, Brehmer B, Fichtner J, Haben B, Wesselmann S, Dieng S.

A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences.

J Patient Rep Outcomes. 2020 Jul 13;4(1):56. doi: 10.1186/s41687-020-00224-7.PMID: 32661594 Free PMC article.

Tully KH, Roghmann F, **Noldus J**, Chen X, Häuser L, Kibel AS, Sonpavde GP, Mossanen M, Trinh QD.

Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

Clin Genitourin Cancer. 2020 Mar 31:S1558-7673(20)30075-6. doi: 10.1016/j.clgc.2020.03.013. Online ahead of print.PMID: 32335060

Berg S, Tully KH, Sahraoui A, Tan WS, Krimphove MJ, Marchese M, Lipsitz SR, **Noldus J**, Trinh QD.

Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urol Oncol. 2020 Jun;38(6):582-589. doi: 10.1016/j.urolonc.2020.02.013. Epub 2020 Mar 23.PMID: 32217041

Benderska-Söder N, Hovanec J, Pesch B, Goebell PJ, Roghmann F, **Noldus J**, Rabinovich J, Wichert K, Gleichenhagen J, Käfferlein HU, Köhler CU, Johnen G, Kernig K, Hakenberg O, Jahn D, Todenhöfer T, Stenzl A, Gleissner J, Gerwert K, El-Mashtoly S, Behrens T, Brüning T, Schmitz-Dräger BJ.

Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.

Urol Oncol. 2020 Mar 18:S1078-1439(20)30007-7. doi: 10.1016/j.urolonc.2020.01.006. Online ahead of print.PMID: 32199755 Review.

Berg S, Hanske J, von Landenberg N, **Noldus J**, Brock M.

Institutional Adoption and Apprenticeship of Fusion Targeted Prostate Biopsy: Does Experience Affect the Cancer Detection Rate?

Urol Int. 2020;104(5-6):476-482. doi: 10.1159/000505654. Epub 2020 Feb 7. PMID: 32036374

Müller G, Butea-Bocu M, Brock O, Hanske J, Pucheril D, **Noldus** J, Otto U. Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.

J Urol. 2020 Mar;203(3):585-590. doi: 10.1097/JU.0000000000000583. Epub 2019 Oct 9. PMID: 31596652

Tully KH, Krimphove MJ, Reese SW, Kibel AS, **Noldus** J, Krasnow RE, Trinh QD, Sonpavde GP, Chang SL, Mossanen M.

Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy.

Urology. 2020 Jan;135:44-49. doi: 10.1016/j.urology.2019.09.029. Epub 2019 Oct 3. PMID: 31586570 Clinical Trial.

Witjes JA, ... Rink M, **Roghmman** F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenck RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19. PMID: 31753752

Horwich A, ... Rink M, **Roghmman** F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenck RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Ann Oncol. 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296. PMID: 31740927

Sibert NT, Dieng S, Oesterle A, Feick G, Carl G, Steiner T, Minner J, **Roghmman** F, Kaftan B, Zengerling F, Hinkel A, Beyer B, Heidenreich A, Harke N, Brehmer B, Pfitzenmaier J, Fichtner J, Neisius A, Hammerer P, Wesselmann S, Kowalski C. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.

World J Urol. 2019 Sep 24. doi: 10.1007/s00345-019-02949-7. Online ahead of print. PMID: 31552467

Moschini M, **Roghmman** F, Xylinas E. Transl Androl Urol. 2019 Feb;8(1):2-4. doi: 10.21037/tau.2018.08.29. PMID: 30976561 Free PMC article. No abstract available.

Botulinumtoxin for bladder disorders. Schulte-Baukloh H, Bauer R, Jost W, Wissel J, **van Ophoven A**.

The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease's management.

Fortschr Neurol Psychiatr. 2019 Feb;87(1):23-30. doi: 10.1055/a-0599-0697. Epub 2018 Dec 3. PMID: 30508871 Review. German.

**van Ophoven A**, Vonde K, Koch W, Auerbach G, Maag KP.

Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials.

Curr Med Res Opin. 2019 Sep;35(9):1495-1503. doi:

10.1080/03007995.2019.1586401. Epub 2019 Mar 19. PMID: 30849922

Re: Birder LA, Wolf-Johnston AS, Jackson EK, Wein AJ, Dmochowski R. Aging increases the expression of vasopressin receptors in both the kidney and urinary bladder. Neurourol Urodyn. 2019 Jan;38(1):393-397.

**van Ophoven A**, Heinze K. Neurourol Urodyn. 2019 Mar;38(3):1026. doi:

10.1002/nau.23933. Epub 2019 Feb 22. PMID: 30801811 No abstract available.

McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, **Noldus J**, Choueiri TK, Kibel AS, Trinh QD.

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.

Ann Surg Oncol. 2019 Jan;26(1):297-305. doi: 10.1245/s10434-018-7035-z. Epub 2018 Nov 14. PMID: 30430324

Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, **Roghmann F**, Rouprêt M, Seiler R, Shariat SF, Qvick B, Babjuk M, Xylinas E;

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.

Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Eur Urol Focus. 2019 Jul;5(4):681-688. doi: 10.1016/j.euf.2017.09.002.

Epub 2017 Oct 23. PMID: 29074050

Tan WS, Berg S, **Cole AP**, Krimphove M, Marchese M, Lipsitz SR, Nabi J, Sammon JD, Choueiri TK, Kibel AS, Sun M, Chang S, Trinh QD.

Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals.

JNCI Cancer Spectr. 2019 Feb 1;3(1):pkz003. doi: 10.1093/jncics/pkz003.

eCollection 2019 Mar. PMID: 31360891 Free PMC article.

Tan WS, Krimphove MJ, **Cole AP**, Marchese M, Berg S, Lipsitz SR, Löppenber B, Nabi J, Abdollah F, Choueiri TK, Kibel AS, Sooriakumaran P, Trinh QD.

Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer.

Clin Genitourin Cancer. 2019 Oct;17(5):e1060-e1068. doi:

10.1016/j.clgc.2019.06.008. Epub 2019 Jun 19. PMID: 31303561

Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. **Cole**, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. *Eur Urol* 2019;75:552-5.

Berg S, **Cole A**, Trinh QD. *Eur Urol*. 2019 Sep;76(3):e76-e77. doi: 10.1016/j.eururo.2019.05.040. Epub 2019 Jun 4. PMID: 31174890 No abstract available.

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

**Cole AP**, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD. *Cancer*. 2019 Apr 15;125(8):1319-1329. doi: 10.1002/cncr.31926. Epub 2019 Jan 11. PMID: 30633323 Free article.

Krimphove MJ, Fletcher SA, **Cole AP**, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Kluth LA, Weissman JS, Trinh QD. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. *J Urol*. 2019 Apr;201(4):735-741. doi: 10.1016/j.juro.2018.10.024. PMID: 30414956 Clinical Trial.

Necchi A, ..., **Roghmman F**, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. *Eur Urol Focus*. 2019 Mar;5(2):242-249. doi: 10.1016/j.euf.2017.05.006. Epub 2017 Jun 3. PMID: 28753897 Free PMC article. Clinical Trial.

Krimphove MJ, Szymaniak J, Marchese M, **Tully KH**, D'Andrea D, Mossanen M, Lipsitz SR, Kilbridge K, Kibel AS, Kluth LA, Shariat SF, Trinh QD. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. *Eur Urol Focus*. 2019 Jun 18:S2405-4569(19)30156-7. doi: 10.1016/j.euf.2019.06.001. Online ahead of print. PMID: 31227463

Krimphove MJ, **Tully KH**, Friedlander DF, Marchese M, Ravi P, Lipsitz SR, Kilbridge KL, Kibel AS, Kluth LA, Ott PA, Choueiri TK, Trinh QD. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. *J Immunother Cancer*. 2019 Nov 7;7(1):289. doi: 10.1186/s40425-019-0782-y. PMID: 31699149 Free PMC article.

Krimphove MJ, **Cole** AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, Sun M, Nabi J, Nguyen PL, Hu JC, Kibel AS, Choueiri TK, Kluth LA, Trinh QD.  
Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.  
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):125-136. doi: 10.1038/s41391-018-0083-4. Epub 2018 Aug 31.PMID: 30171227

Haeuser L, Dahlkamp L, **Noldus** J, Roghmann F.  
The value of nephrometry scoring systems in prediction of conversion to radical nephrectomy in patients scheduled for nephron-sparing surgery.  
Ann Transl Med. 2019 Nov;7(22):704. doi: 10.21037/atm.2019.11.09.PMID: 31930105 Free PMC article. No abstract available.

**Tully KH**, Krimphove Md MJ, Huynh MJ, Marchese M, Kibel AS, Noldus J, Kluth LA, McGregor B, Chang SL, Trinh QD, Mossanen M.  
Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis.  
World J Urol. 2019 Nov 20. doi: 10.1007/s00345-019-03003-2. Online ahead of print.PMID: 31748954

Tully KH, Nguyen DD, Herzog P, Jin G, **Noldus** J, Nguyen PL, Kibel AS, Sun M, McGregor B, Basaria S, Trinh QD.  
Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.  
Eur Urol Oncol. 2019 Oct 14:S2588-9311(19)30129-4. doi: 10.1016/j.euo.2019.08.003. Online ahead of print.PMID: 31624049  
Reply by Authors.

Dahlkamp L, Haeuser L, Winnekendonk G, von Bodman C, Frey UH, Epplen R, Palisaar RJ, Bach P, **Noldus** J, Brock M, Roghmann F.J Urol. 2019 Nov;202(5):897-898. doi: 10.1097/01.JU.0000580464.59886.eb. Epub 2019 Oct 9.PMID: 31430241  
No abstract available.

Hanske J, Roghmann F, **Noldus** J, Brock M.  
Editorial: early PSA-testing after radical prostatectomy-the truth behind the scenes.  
Transl Androl Urol. 2019 Jul;8(Suppl 3):S307-S309. doi: 10.21037/tau.2019.06.08.PMID: 31392154 Free PMC article. No abstract available.

Hanske J, Ostholt J, Roghmann F, Müller G, Braun K, Gomez B, von Landenberg N, von Bodman C, Palisaar RJ, Liermann D, **Noldus** J, Brock M.  
Salvage lymph node dissection in hormone-naïve men: How effective is surgery?  
Urol Oncol. 2019 Nov;37(11):812.e17-812.e24. doi: 10.1016/j.urolonc.2019.06.023. Epub 2019 Jul 18.PMID: 31327750

Dahlkamp L, Haeuser L, Winnekendonk G, von Bodman C, Frey UH, Epplen R, Palisaar RJ, Bach P, **Noldus** J, Brock M, Roghmann F.  
Interdisciplinary Comparison of PADUA and R.E.N.A.L. Scoring Systems for Prediction of Conversion to Nephrectomy in Patients with Renal Mass Scheduled for Nephron Sparing Surgery.  
J Urol. 2019 Nov;202(5):890-898. doi: 10.1097/JU. Epub 2019 Oct 9.PMID: 31145034

Tully KH, Roghmann F, Pastor J, **Noldus** J, von Bodman C.  
Parastomal Hernia Repair With 3-D Mesh Implants After Radical Cystectomy and Ileal Conduit Urinary Diversion - A Single-center Experience Using a Purpose Made Alloplastic Mesh Implant.  
Urology. 2019 Sep;131:245-249. doi: 10.1016/j.urology.2019.05.006. Epub 2019 May 23.PMID: 31129194

Köhler CU, Bonberg N, Ahrens M, Behrens T, Hovanec J, Eisenacher M, **Noldus** J, Deix T, Braun K, Gohlke H, Walter M, Tannapfel A, Tam Y, Sommerer F, Marcus K, Jöckel KH, Erbel R, Cantor CR, Käfferlein HU, Brüning T.  
Noninvasive diagnosis of urothelial cancer in urine using DNA hypermethylation signatures-Gender matters.  
Int J Cancer. 2019 Nov 15;145(10):2861-2872. doi: 10.1002/ijc.32356. Epub 2019 May 16.PMID: 31008534

Tully K, Palisaar RJ, Brock M, Bach P, von Landenberg N, Löppenber B, von Bodman C, **Noldus** J, Roghmann F.  
Transurethral resection of bladder tumours: established and new methods of tumour visualisation.  
Transl Androl Urol. 2019 Feb;8(1):25-33. doi: 10.21037/tau.2018.12.12.PMID: 30976565 Free PMC article. Review.

Witzke KE, Großerueschkamp F, Jütte H, Horn M, Roghmann F, von Landenberg N, Bracht T, Kallenbach-Thieltges A, Käfferlein H, Brüning T, Schork K, Eisenacher M, Marcus K, **Noldus** J, Tannapfel A, Sitek B, Gerwert K.  
Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.  
Am J Pathol. 2019 Mar;189(3):619-631. doi: 10.1016/j.ajpath.2018.11.018. Epub 2019 Feb 12.PMID: 30770125 Free article. Clinical Trial.

Friedlander DF, von Landenberg N, Löppenber B, **Noldus** J, Lipsitz SR, Cole AP, Abdollah F, Nguyen PL, Choueiri TK, Kibel AS, Trinh QD.  
Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign.  
J Urol. 2019 Apr;201(4):728-734. doi: 10.1097/JU.PMID: 30633112

Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, **Noldus** J, Shariat SF, Kibel AS, Trinh QD, Mossanen M.  
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?  
Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.PMID: 30620387 Free article.

McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, **Noldus** J, Choueiri TK, Kibel AS, Trinh QD.  
Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.  
Ann Surg Oncol. 2019 Jan;26(1):297-305. doi: 10.1245/s10434-018-7035-z. Epub 2018 Nov 14.PMID: 30430324

Berg S, **Cole** AP, Krimphove MJ, Nabi J, Marchese M, Lipsitz SR, Noldus J, Choueiri TK, Kibel AS, Trinh QD.

Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.

Eur Urol. 2019 Apr;75(4):552-555. doi: 10.1016/j.eururo.2018.10.032. Epub 2018 Nov 10. PMID: 30420255

Lang K, Kahveci S, Bonberg N, Wichert K, Behrens T, Hovanec J, Roghmann F, **Noldus** J, Tam YC, Tannapfel A, Käfferlein HU, Brüning T.

TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.

Int J Mol Sci. 2019 Sep 11;20(18):4483. doi: 10.3390/ijms20184483. PMID: 31514337  
Free PMC article.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, **Noldus** J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A;

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

German Network Of Kidney Cancer. Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17. PMID: 30121370

#### **van Ophoven A.**

[Sacral neuromodulation for refractory overactive bladder].

Urologe A. 2018 Nov;57(11):1375-1388. doi: 10.1007/s00120-018-0777-1. PMID: 30310935 German.

Hanske J, Müller G, **van Ophoven A**, von Landenberg N, Roghmann F, Palisaar RJ, von Bodman C, Noldus J, Brock M.

De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer.

Neurourol Urodyn. 2018 Aug;37(6):1988-1995. doi: 10.1002/nau.23545. Epub 2018 Mar 5. PMID: 29504654

Moschini M, **Roghmann** F, Xylinas E.

The present and future of non-muscle invasive bladder cancer.

Transl Androl Urol. 2019 Feb;8(1):1. doi: 10.21037/tau.2019.02.02. PMID: 30976560  
Free PMC article. No abstract available.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, **Roghmann** F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists' Working Group on Urothelial Carcinoma of the European Association of Urology.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Eur Urol Focus. 2018 Dec 14:S2405-4569(18)30382-1. doi:

10.1016/j.euf.2018.12.002. Online ahead of print. PMID: 30559065

von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, Shariat SF, Xylinas E, **Roghmans** F; Young Academic Urologists' Working Group on Urothelial Cancer of the European Association of Urology.  
Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.  
Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3. PMID: 29506940 Clinical Trial

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, **Roghmans** F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.  
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.  
Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. PMID: 29496372 Review.

**Berg** S, Nabi J, Trinh QD.  
Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy.  
JAMA Oncol. 2018 Nov 1;4(11):1619-1620. doi: 10.1001/jamaoncol.2018.3536. PMID: 30422246 No abstract available.

Fletcher SA, Harmouch SS, Krimphove MJ, **Cole** AP, Berg S, Gild P, Preston MA, Sonpavde GP, Kibel AS, Sun M, Choueiri TK, Trinh QD.  
Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.  
World J Urol. 2018 Nov;36(11):1767-1774. doi: 10.1007/s00345-018-2371-y. Epub 2018 Jun 14. PMID: 29948050

Fletcher SA, **Cole** AP, Berg S, Pucheril D, Trinh QD.  
Adoption of robotic surgery: driven by market competition or a desire to improve patient care?  
Lancet Oncol. 2018 Feb;19(2):e66. doi: 10.1016/S1470-2045(18)30021-4. PMID: 29413467 No abstract available.

Fletcher SA, **Berg** S, Trinh QD.  
The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle.  
BJU Int. 2018 Jan;121(1):4-5. doi: 10.1111/bju.14052. PMID: 29314538 Free article. No abstract available.

Berg S, Fletcher SA, **Cole** AP, Trinh QD.  
Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard.  
Cancer. 2018 Mar 15;124(6):1299-1300. doi: 10.1002/cncr.31201. Epub 2017 Dec 19. PMID: 29266175 Free article. No abstract available.

**Cole** AP, Hanske J, Jiang W, Kwon NK, Lipsitz SR, Kathrins M, Learn PA, Sun M, Haider AH, Basaria S, Trinh QD.



Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men.

BJU Int. 2018 May;121(5):811-818. doi: 10.1111/bju.14149. Epub 2018 Feb 27. PMID: 29383868 Free article.

Gupta S, **Cole** AP, Marchese M, Wang Y, Speed JM, Fletcher SA, Nabi J, Berg S, Lipsitz SR, Choueiri TK, Chang SL, Kibel AS, Uhlig A, Trinh QD.

Use of Preventive Health Services Among Cancer Survivors in the U.S.

Am J Prev Med. 2018 Dec;55(6):830-838. doi: 10.1016/j.amepre.2018.07.021. Epub 2018 Oct 21. PMID: 30352719

Berg S, Cole AP, Fletcher SA, Pucheril D, Nabi J, Lipsitz SR, Chang SL, Sun M, **Noldus** J, Harshman LC, Choueiri TK, Trinh QD.

Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.

Urol Oncol. 2018 Sep;36(9):400.e15-400.e22. doi: 10.1016/j.urolonc.2018.06.005. PMID: 30274640

Bach P, Reicherz A, Teichman J, Dahlkamp L, von Landenberg N, Palisaar RJ, **Noldus** J, von Bodman C.

Short-term external ureter stenting shows significant benefit in comparison to routine double-J stent placement after ureterorenoscopic stone extraction: A prospective randomized trial - the Fast track stent study (FaST).

Int J Urol. 2018 Aug;25(8):717-722. doi: 10.1111/iju.13711. Epub 2018 Jun 7. PMID: 29882261 Clinical Trial.

**Noldus** J, Niegisch G, Pycha A, Karl A.

[Radical cystectomy and urinary diversion-what is important ?].

Urologe A. 2018 Jun;57(6):673-678. doi: 10.1007/s00120-018-0648-9. PMID: 29696301 Review. German.

Hanske J, Müller G, van Ophoven A, von Landenberg N, Roghmann F, Palisaar RJ, von Bodman C, **Noldus** J, Brock M.

De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer.

Neurourol Urodyn. 2018 Aug;37(6):1988-1995. doi: 10.1002/nau.23545. Epub 2018 Mar 5. PMID: 29504654

von Landenberg N, Speed JM, Cole AP, Seisen T, Lipsitz SR, Gild P, Menon M, Kibel AS, Roghmann F, **Noldus** J, Sun M, Trinh QD.

Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.

Urol Oncol. 2018 Feb;36(2):78.e13-78.e19. doi: 10.1016/j.urolonc.2017.10.021. Epub 2017 Nov 21. PMID: 29169845

Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM, Burger M, Protzel C, Hakenberg OW, von Landenberg N, Roghmann F, **Noldus** J, Nuhn P, Pycha A, Rink M, Chun FK, May M, Fisch M, Aziz A; PROMETRICS 2011 Study Group.

Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.

BJU Int. 2018 Jan;121(1):101-110. doi: 10.1111/bju.14012. Epub 2017 Oct 11.PMID: 28905486 Clinical Trial.

Vetterlein MW, ... Hakenberg OW, Roghmann F, Palisaar RJ, **Noldus** J, Pycha A, Bastian PJ, Trinh QD, Xylinas E, Shariat SF, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 Study Group.Eur Urol Focus. Variation in the use of active surveillance for low-risk prostate cancer.2018 Mar;4(2):252-259. doi: 10.1016/j.euf.2016.07.001. Epub 2016 Jul 18.PMID: 28753775

Löppenberg B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, Barry H, Lipsitz SR, Menon M, Abdollah F, Sammon JD, Sun M, Choueiri TK, Kibel AS, Trinh QD. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. Cancer Cytopathol. 2018 Jan 1;124(1):55-64. doi: 10.1002/cncr.30983. Epub 2017 Sep 13.PMID:28902401

#### Klinik für Strahlentherapie und Radio-Onkologie

**Muecke R**, Waldschock K, Schomburg L, Micke O, Buentzel J, Kisters K, **Adamietz** IA, Huebner J: Whole Blood Selenium Levels and Selenium Supplementation in Patients Treated in a Family Doctor Practice in Golssen (State of Brandenburg, Germany): A Laboratory Study. Integr Cancer Ther 2018, 17(4):1132-1136.

**Nguemgo Kouam P**, Rezniczek GA, Kochannek A, Priesch-Grzeszkowiak B, Hero T, Adamietz IA, Buhler H: Robo1 and vimentin regulate radiation-induced motility of human glioblastoma cells. PLoS One 2018, 13(6):e0198508.

**Adamietz IA**: Komplikationen statt Überlebensvorteil und lokale Rezidivfreiheit nach fruher radikaler Zystektomie bei muskelinvasivem Harnblasenkarzinom im Vergleich zur multimodalen Erhaltungstherapie. Strahlenther Onkol 2018, 194(4):358-359.

**Adamietz IA**: Einfluss der prophylaktischen Ganzhirnbestrahlung auf das Gesamtüberleben beim fortgeschrittenen kleinzelligen Bronchialkarzinom : Ergebnisse einer japanischen multizentrischen, randomisierten Open-Label-Phase-III-Studie. Strahlenther Onkol 2018, 194(3):264-265.

Budde M, **Adamietz IA**, Sommer H, Hermani H: Dosimetrische Verifikation von MammoSite-Bestrahlungsplanen mit Monte-Carlo-Simulationen sowie Messungen mit einem 2D-Ionisationskammer-Array. Z Med Phys 2018, 28(2):158-163.

Kriz J, Seegenschmiedt HM, Bartels A, Micke O, **Muecke R**, Schaefer U, Haverkamp U, Eich HT: Updated strategies in the treatment of benign diseases-a patterns of care study of the german cooperative group on benign diseases. Adv Radiat Oncol 2018, 3(3):240-244.

Micke O, Ugrak E, Bartmann S, Adamietz IA, Schaefer U, Bueker R, Kisters K, Heinrich Seegenschmiedt M, Fakhrian K, **Muecke R**: Radiotherapy for calcaneodynia, achillodynia, painful gonarthrosis, bursitis trochanterica, and painful shoulder syndrome - Early and late results of a prospective clinical quality assessment. *Radiat Oncol* 2018, 13(1):71.

**Muecke R**, Micke O, Schomburg L, Buentzel J, Kisters K, **Adamietz IA**, Akte: Selenium in Radiation Oncology-15 Years of Experiences in Germany. *Nutrients* 2018, 10(4).

Niewald M, Micke O, **Muecke R**: Don't Forget Radiotherapy. *Dtsch Arztebl Int* 2018, 115(19):342-343.

**Adamietz IA**, Wolanczyk MJ: Functional recovery after surgical stabilization and postoperative radiotherapy due to metastases of long bones. *Strahlenther Onkol* 2019, 195(4):335-342.

**Hero T**, Buhler H, Kouam PN, Priesch-Grzeszowiak B, Lateit T, **Adamietz IA**: The Triple-negative Breast Cancer Cell Line MDA-MB 231 Is Specifically Inhibited by the Ionophore Salinomycin. *Anticancer Res* 2019, 39(6):2821-2827.

**Nguemgo Kouam PN**, Rezniczek GA, Adamietz IA, Buhler H: Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin. *BMC Cancer* 2019, 19(1):958.

**Nguemgo Kouam P**, Buhler H, Hero T, Adamietz IA: The increased adhesion of tumor cells to endothelial cells after irradiation can be reduced by FAK-inhibition. *Radiat Oncol* 2019, 14(1):25.

Ridwan S, Greschus S, **Bostrom J**, Barrera J, Esche J, Zur B, Klingmuller D, Bostrom A: Spontaneous Aneurysmal Subarachnoid Hemorrhage and Related Cortisol and Immunologic Alterations: Impact on Patients' Health-related Quality of Life. *J Neurol Surg A Cent Eur Neurosurg* 2019, 80(5):371-380.

Staresina BP, Reber TP, Niediek J, **Bostrom J**, Elger CE, Mormann F: Recollection in the human hippocampal-entorhinal cell circuitry. *Nat Commun* 2019, 10(1):1503.

Reber TP, Bausch M, Mackay S, **Bostrom J**, Elger CE, Mormann F: Representation of abstract semantic knowledge in populations of human single neurons in the medial temporal lobe. *PLoS Biol* 2019, 17(6):e3000290.

Coenen VA, Bewernick BH, Kayser S, Kilian H, **Bostrom J**, Greschus S, Hurlemann R, Klein ME, Spanier S, Sajonz B et al: Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial. *Neuropsychopharmacology* 2019, 44(7):1224-1232.

Juniku N, Micke O, Seegenschmiedt MH, **Muecke R**: Radiotherapy for painful benign skeletal disorders : Results of a retrospective clinical quality assessment. *Strahlenther Onkol* 2019, 195(12):1068-1073.

Piroth MD, **Mucke R**, Micke O: Antioxidantien und Selen gehören nicht in einen Topf - Bewertung der Supplementierung während Chemo- oder Strahlentherapie bei Brustkrebs. *Strahlenther Onkol* 2019, 195(9):857-860.

Micke O, Buntzel J, **Mucke R**, Hubner J: Consider Alternative Medicine. *Dtsch Arztebl Int* 2019, 116(13):222.

Buntzel J, Micke O, Kisters K, Buntzel J, **Mucke R**: Malnutrition and Survival - Bioimpedance Data in Head Neck Cancer Patients. *In Vivo* 2019, 33(3):979-982.

Ott OJ, Micke O, **Mucke R**, Niewald M, Rodel F, Schafer U, Seegenschmiedt MH, Arenas M, Frey B, Gaipf US et al: Low-dose radiotherapy: Mayday, mayday. We've been hit! *Strahlenther Onkol* 2019, 195(4):285-288.

**Adamietz IA**: Superoxiddismutasemimetikum (GC4419) vs. Placebo zur Reduktion von schweren oralen Mukosiden infolge simultaner Radiochemotherapie mit Cisplatin bei Kopf-Hals-Tumoren: randomisierte, doppelblinde Phase-IIb-Studie. *Strahlenther Onkol* 2020, 196(9):834-836.

Kakkassery V, Emmert S, **Adamietz IA**, Kovacs G, Junemann AM, Otte C, Zimbelmann M, Brosig A, Grisanti S, Heindl LM: Alternative Behandlungsoptionen beim Basalzellkarzinom am Auge. *Ophthalmologe* 2020, 117(2):113-123.

Unruh-Pinheiro A, Hill MR, Weber B, **Bostrom J**, Elger CE, Mormann F: Single-Neuron Correlates of Decision Confidence in the Human Medial Temporal Lobe. *Curr Biol* 2020.

Krom AJ, Marmelshtein A, Gelbard-Sagiv H, Tankus A, Hayat H, Hayat D, Matot I, Strauss I, Fahoum F, Soehle M; **Bostrom J**, Mormann F, Nir Y: Anesthesia-induced loss of consciousness disrupts auditory responses beyond primary cortex. *Proc Natl Acad Sci U S A* 2020, 117(21):11770-11780.

Pintea B, Surges R, **Bostrom J**: Headache Perception in an Epilepsy Patient with Neuromodulation by Anterior Thalamic Nuclei Deep Brain Stimulation: A Case Report. *J Neurol Surg A Cent Eur Neurosurg* 2020, 81(4):368-371.

#### Klinik für Hämatologie und Internistische Onkologie

**Schultheis B**, **Strumberg D**, Kuhlmann J, Wolf M, Link K, Seufferlein T, Kaufmann J, Feist M, Gebhardt F, Khan M, Stintzing S, Pelzer U. Safety, Efficacy and Pharmacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/Ila Study. *Cancers (Basel)*. 2020 Oct 26;12(11):E3130.

Voso MT, ... Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, **Schultheis B**, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H,

Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. *Blood Adv.* 2020 Oct 13;4(19):4945-4954.

Janssen M, ... Jäger D, **Schultheis** B, Schlenk RF, Leo A, Meuer S, Weigand MA, Motsch J, Merle U, Denking CM, Müller-Tidow C. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. *Trials.* 2020 Oct 6;21(1):828.

Kuendgen A, ...Machherndl-Spandl S, **Schultheis** B, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. *Leukemia.* 2020 Jun 29.

Struller F, Horvath P, Solass W, Weinreich FJ, **Strumberg** D, Kokkalis MK, Fischer I, Meisner C, Königsrainer A, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. *Ther Adv Med Oncol.* 2019 May 13;11:1758835919846402.

Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, **Strumberg** D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. *Breast.* 2019 Jun;45:22-28.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, **Strumberg** D, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N Engl J Med.* 2019 Feb 21;380(8):720-728.

Bates D, **Schultheis** B, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, Levy RM, Hunter CW. Neuromodulation of the Dorsal Root Ganglion for Chronic Postsurgical Pain. *Pain Med.* 2019 Jun 1;20(Suppl 1):S2-S12. doi: 10.1093/pm/pnz075. PMID: 31152178 Free PMC article. Review.

Antony AB, **Schultheis** B, Jolly SM, Bates D, Hunter CW, Levy RM. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Pain Med. 2019 Jun 1;20(Suppl 1):S41-S46. doi: 10.1093/pm/pnz072. PMID: 31152174 Free PMC article.

Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigteroth S, Cohnen J, **Díaz-Carballo D**, Bockisch A, Zieren J, Giger-Pabst U.  
Scintigraphic peritoneography reveals a non-uniform <sup>99m</sup>Tc-Perchnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model.  
Surg Endosc. 2018 Jan;32(1):166-174.

**Díaz-Carballo D**, Saka S, Klein J, Rennkamp T, Acikelli AH, Malak S, Jastrow H, Wennemuth G, Tempfer C, Schmitz I, Tannapfel A, **Strumberg D**.  
A Distinct Oncogenerative Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity.  
Cancer Res. 2018 May 1;78(9):2318-2331.

Tempfer CB, Tischoff I, Dogan A, Hilal Z, **Schultheis B**, Kern P, Rezniczek GA.  
Neuroendocrine carcinoma of the cervix: a systematic review of the literature.  
BMC Cancer. 2018 May 4;18(1):530.

Dogan A, Kern P, **Schultheis B**, Häusler G, Rezniczek GA, Tempfer CB.  
Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.  
BMC Cancer. 2018 Apr 24;18(1):463. doi: 10.1186/s12885-018-4369-7.

Rapi V, Dogan A, **Schultheis B**, Hartmann F, Rezniczek GA, Tempfer CB.  
Melanoma of the Vagina: Case Report and Systematic Review of the Literature.  
Anticancer Res. 2018 Dec;37(12):6911-6920.

**Díaz-Carballo D**, Klein J, Acikelli AH, Wilk C, Saka S, Jastrow H, Wennemuth G, Dammann P, Giger-Pabst U, Khosrawipour V, Rassow J, Nienen M, **Strumberg D**.  
Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cells.  
Oncotarget. 2018 Oct 7;8(56):95945-95964.

**Schultheis B**, Reuter D, Ebert MP, ... Steinmetz T, Bulitta M, **Strumberg D**.  
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.  
Ann Oncol. 2018 Oct 1;28(10):2429-2435.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, **Strumberg D**, **Schultheis B**, Dy GK, Zalcmán G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.  
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2018 Jun 6;116(12):1505-1512.

Khosrawipour V, **Díaz-Carballo D**, Acikelli AH, Khosrawipour T, Falkenstein TA, Wu D, Zieren J, Giger-Pabst U.

Cytotoxic effect of different treatment parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on the in vitro proliferation of human colonic cancer cells.

World J Surg Oncol. 2018 May 2;15(1):94.

Khosrawipour V, Khosrawipour T, Hedayat-Pour Y, **Diaz-Carballo D**, Bellendorf A, Böse-Ribeiro H, Mücke R, Mohanaraja N, Adamietz IA, Fakhrian K.

Effect of Whole-abdominal Irradiation on Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Post-mortem Swine Model.

Anticancer Res. 2018 Apr;37(4):1677-1680.

## KLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE

Dörk T, Hillemanns P, **Tempfer C**, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. 2020. *Cancers*. 12 (9). PMID: 32854222. DOI: 10.3390/cancers12092407.

Emons G, Mustea A, **Tempfer C**. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. 2020. *Cancers*. 12 (9). PMID: 32906618. DOI: 10.3390/cancers12092535.

Hilal Z, **Tempfer CB**, Burgard L, Rehman S, Rezniczek GA. How long is too long? Application of acetic acid during colposcopy: A prospective study. 2020. *American Journal of Obstetrics and Gynecology*. PMID: 31981505. DOI: 10.1016/j.ajog.2020.01.038.

Hillemanns P, **Tempfer C**, Beckmann MW, Küppers V, Quaas J. Statement of the AGO and AG-CPC on the Aftercare/Follow-up for Surgical Procedures of the Lower Genital Tract after the Introduction of a New Cancer Screening Guideline. 2020. *Geburtshilfe und Frauenheilkunde*. 80 (8):809–12. PMID: 32817987. DOI: 10.1055/a-1193-5136.

Rezniczek GA, Hecken JM, Rehman S, Dogan A, **Tempfer CB**, Hilal Z. Syringe or mask? Loop electrosurgical excision procedure under local or general anesthesia: a randomized trial. 2020 *American Journal of Obstetrics and Gynecology*. PMID: 32585223. DOI: 10.1016/j.ajog.2020.06.041.

Sgarbura O, Villeneuve L, Alyami M, **Bakrin N**, Torrent JJ, Eveno C, Hübner M. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? 2020. *European Journal of Surgical Oncology*. PMID: 32900609. DOI: 10.1016/j.ejso.2020.08.020.

**Tempfer CB**, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. 2020. *Cancers*. 12 (8). PMID: 32781573. DOI: 10.3390/cancers12082195.

Archid R, Solass W, **Tempfer C**, Koenigsrainer A, Adolph M, Reymond MA, Wilson RB. Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis. 2019. *International Journal of Molecular Sciences*. 20 (21). PMID: 31683709. DOI: 10.3390/ijms20215444.

Denschlag D, .... Schmidt D, Strauss H-G, **Tempfer C**, Thiel F, Ulrich U, Vogl T, Vordermark D, Gass P, Beckmann MW. Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). 2019. *Geburtshilfe und Frauenheilkunde*. 79 (10):1043–60. PMID: 31656317. DOI: 10.1055/a-0882-4116.

Emons G, **Tempfer C**, Battista MJ, Mustea A, Vordermark D. Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019 Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO). 2019. *Geburtshilfe und Frauenheilkunde*. 79 (12):1273–7. PMID: 31875857. DOI: 10.1055/a-1019-7720.

Hilal Z, **Tempfer CB**, **Rezniczek GA**. Treatment of Cervical Dysplasia by Clinicians Who Perform Colposcopy in German-speaking Countries - a Questionnaire-based Study. 2019. *Geburtshilfe und Frauenheilkunde*. 79 (2):189–97. PMID: 30792549. DOI: 10.1055/a-0828-7831.

Hillemanns P, Brucker S, Holthaus B, Kimmig R, Lampe B, Runnebaum I, Ulrich U, Wallwiener M, Fehm T, **Tempfer C**. Updated Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO) and the Gynecological Endoscopy Working Group (AGE) of the German Society of Gynecology and Obstetrics (DGGG) on the Randomized Study Comparing Minimally Invasive with Abdominal Radical Hysterectomy for Early-stage Cervical Cancer (LACC). 2019. *Geburtshilfe und Frauenheilkunde*. 79 (2):145–7. PMID: 30792544. DOI: 10.1055/a-0824-7929.

Kouam PN, **Rezniczek GA**, Adamietz IA, Bühler H. Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin. 2019. *BMC Cancer*. 19 (1):958. PMID: 31619190. DOI: 10.1186/s12885-019-6219-7.

Ortmann O, Treeck O, Inwald EC, Emons G, **Tempfer C**. Hormone replacement therapy and risk of breast cancer. 2019. *Der Gynäkologe*. 52 (8):605–16. DOI: 10.1007/s00129-019-4472-0.

Rezniczek GA, Grunwald C, Hilal Z, Scheich J, Reifenberger G, Tannapfel A, **Tempfer CB**. ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin). 2019. *Anticancer Research*. 39 (3):1267–73. PMID: 30842157. DOI: 10.21873/anticancerres.13237.

**Tempfer CB**, Kern P, Dogan A, Hilal Z, Rezniczek GA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: A systematic review. 2019. *Clinical & Experimental Metastasis*. 36 (4):321–9. PMID: 31089843. DOI: 10.1007/s10585-019-09970-5.

Bakrin N, **Tempfer C**, Scambia G, Simone M de, Gabriel B, Grischke E-M, Rau B, Oncologic F, HIPEC FOG.



PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intraperitoneal Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. 2018. *Pleura and Peritoneum*. 3 (3). PMID: 30911662. DOI: 10.1515/pap-2018-0114.

Breitbach G-P, Sklavounos P, Veith C, Costa S-D, Kuhn W, Solomayer E-F, Juhasz-Boess I, **Tempfer C**.

Oral etoposide for metastatic choriocarcinoma: A case report and review of guidelines. 2018. *Archives of Gynecology and Obstetrics*. PMID: 30569343. DOI: 10.1007/s00404-018-5016-x.

Diaz-Carballo D, Saka S, Klein J, Rennkamp T, Acikelli AH, Malak S, Jastrow H, Wennemuth G, **Tempfer CB**, Schmitz I, Tannapfel A, Strumberg D. A distinct oncogenerative multinucleated cancer cell serves as a source of stemness and tumor heterogeneity. 2018. *Cancer Research*. PMID: 29440172. DOI: 10.1158/0008-5472.CAN-17-1861.

Dogan A, Kern P, Schultheis B, Häusler G, **Rezniczek GA, Tempfer CB**. Radiogenic angiosarcoma of the breast: Case report and systematic review of the literature. 2018. *BMC Cancer*. 18 (1):463. PMID: 29690864. DOI: 10.1186/s12885-018-4369-7.

Falkenstein TA, Götze TO, Ouaiissi M, **Tempfer CB**, Giger-Pabst U, Demtröder C. First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer. 2018. *Anticancer Research*. 38 (1):373–8. PMID: 29277797. DOI: 10.21873/anticancer.12232.

Giger-Pabst U, Demtröder C, Falkenstein TA, Ouaiissi M, Götze TO, Rezniczek GA, **Tempfer CB**. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma. 2018. *BMC Cancer*. 18 (1):442. PMID: 29669524. DOI: 10.1186/s12885-018-4363-0.

Giger-Pabst U, **Tempfer CB**. How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures. 2018. *Journal of Gastrointestinal Surgery*. PMID: 30132291. DOI: 10.1007/s11605-018-3916-5.

Goetze OT, Al-Batran S-E, Pabst U, Reymond M, **Tempfer C**, Bechstein WO, Bankstahl U, Gockel I, Königsrainer A, Kraus T, Mönig SP, Rau B, Schwarzbach M, Piso P. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gastrointestinal adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO. 2018. *Pleura and Peritoneum*. 3 (2):159. PMID: 30911658. DOI: 10.1515/pp-2018-0113.

Hilal Z, Alici F, **Tempfer CB**, Rath K, Nar K, Rezniczek GA. Mozart for Reducing Patient Anxiety During Colposcopy: A Randomized Controlled Trial. 2018. *Obstetrics and Gynecology*. 132 (4):1047–55. PMID: 30204685. DOI: 10.1097/AOG.0000000000002876.

Hilal Z, Rezniczek GA, Alici F, Kumpernatz A, Dogan A, Alieva L, **Tempfer CB**. Loop Electrosurgical Excision Procedure (LEEP) with or without Intraoperative Colposcopy: A Randomized Trial. 2018.

*American Journal of Obstetrics and Gynecology*. PMID: 30063903.

DOI: 10.1016/j.ajog.2018.07.023.

Hillemanns P, Brucker S, Holthaus B, Lampe B, Runnebaum I, Ulrich U, Wallwiener M, Solomayer E, Fehm T, **Tempfer C**. Comment on the LACC Trial Investigating Early-stage Cervical Cancer by the Uterus Commission of the Study Group for Gynecologic Oncology (AGO) and the Study Group for Gynecologic Endoscopy (AGE) of the German Society for Gynecology and Obstetrics (DGGG). 2018.

*Geburtshilfe und Frauenheilkunde*. 78 (8):766–7. PMID: 30158715. DOI: 10.1055/a-0655-8112.

Jablonka A, Scheich J, Jacobsen F, Hirsch T, Hagouan M, Lehnhardt M, **Tempfer CB, Rezniczek GA**. Influence of preadipocyte-conditioned medium on the proliferation and invasive potential of breast cancer cell lines in vitro. 2018. *Archives of Gynecology and Obstetrics*. PMID: 30251158. DOI: 10.1007/s00404-018-4910-6.

Nguemgo Kouam P, **Rezniczek GA**, Kochannek A, Priesch-Grzeszkowiak B, Hero T, **Adamietz IA**, Bühler H. Robo1 and vimentin regulate radiation-induced motility of human glioblastoma cells. 2018. *PLoS One*. 13 (6):e0198508. PMID: 29864155.

DOI: 10.1371/journal.pone.0198508.

Seebacher V, Sturdza A, Bergmeister B, Polterauer S, Grimm C, Reinthaller A, **Hilal Z**, Aust S. Factors associated with post-relapse survival in patients with recurrent cervical cancer: The value of the inflammation-based Glasgow Prognostic Score. 2018. *Archives of Gynecology and Obstetrics*. PMID: 30535923.

DOI: 10.1007/s00404-018-4993-0.

**Tempfer C**, Giger-Pabst U, Hilal Z, Dogan A, Rezniczek GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: Systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. 2018. *Archives of Gynecology and Obstetrics*. PMID: 29869089. DOI: 10.1007/s00404-018-4784-7.

**Tempfer C**, Steinke-Lange V, Aretz S, Hanf V. Epidemiology, risk factors and genetics of endometrial cancer. 2018. *Der Gynäkologe*. 51 (12):1000–8.

DOI: 10.1007/s00129-018-4330-5.

**Tempfer CB**, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. 2018. *Gynecologic Oncology*. PMID: 29743140. DOI: 10.1016/j.ygyno.2018.05.001.

**Tempfer CB**, Hilal Z, Dogan A, Petersen M, Rezniczek GA. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis. 2018.

*European Journal of Surgical Oncology*. PMID: 29753612.

DOI: 10.1016/j.ejso.2018.04.020.

Tempfer CB, Tischoff I, Dogan A, Hilal Z, Schultheis B, Kern P, Rezniczek GA. Neuroendocrine carcinoma of the cervix: A systematic review of the literature. 2018. *BMC Cancer*. 18 (1):530. PMID: 29728073. DOI: 10.1186/s12885-018-4447-x.

Emons G, ..., **Tempfer C**, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. 2018

*Geburtshilfe und Frauenheilkunde*. 78 (11):1089–109. PMID: 30581199.

DOI: 10.1055/a-0715-2964.

Emons G, .... Runnebaum I, **Tempfer C**, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. 2018.

*Geburtshilfe und Frauenheilkunde*. 78 (10):949–71. PMID: 30364388.

DOI: 10.1055/a-0713-1218.

Emons G, **Tempfer C**, Battista MJ, Mustea A, Vordermark D. Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study. 2018.

*Geburtshilfe und Frauenheilkunde*. 78 (10):923–6. PMID: 30364421. DOI: 10.1055/a-0658-1918.

## Publikationen Institut für Pathologie

Li Y, Schaarschmidt B, Umutlu L, Forsting M, Demircioglu A, Koch AK, Martin O, Herrmann K, Juette H, **Tannapfel A**, Langhorst J

F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.

*Eur J Nucl Med Mol Imaging*. 2020;47(4): 768-777

Spiesbach K, **Tannapfel A**, Mossner J, Engeland K

TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor (vol 114, pg 555, 2005)

*Int J Cancer*. 2020;146(5): E27-E27

Thum S, **Tannapfel A**, Hilje T, Sen Gupta R

Autopsy reveals rare cause of death

*Pathologe*. 2020;41(1): 73-78

Witzke KE, Großerueschkamp F, Jütte H, Horn M, Roghmann F, von Landenberg N, Bracht T, Kallenbach-Thieltges A, Käfferlein H, Brüning T, Schork K, Eisenacher M, Marcus K,

Noldus J, **Tannapfel A**, Sitek B, Gerwert K

Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer.

Am J Pathol. 2019;189(3): 619-631

Bonella F, Campo I, Boerner E, Theegarten D, **Guzman J**, Costabel U

Potential Clinical Utility of MUC5B and TOLLIP Single Nucleotide Polymorphisms (SNP) in the Management of Patients with IPF: Preliminary Results

Am J Respir Crit Care Med. 2019;199: -

Geissler M, **Tannapfel A**, Reinacher-Schick A, Martens U, Ricke J, Riera-Knorrenschild J, Kanzler S, Held S, Heinemann V, Seufferlein T, Modest D

Final results of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first line treatment in patients with RAS wild -type metastatic colorectal cancer (mCRC)

Ann Oncol. 2019;30 4

Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, Taubert H, Wullich B, Weyerer V, Stoehr R, Zengerling F, Bolenz C, Breyer J, Burger M, Porubsky S, Hartmann A, Erben P, Eckstein M, **Juette H**

Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Ann Oncol. 2019;30 5

Jarczyk J, Wirtz R, Roghmann F, **Juette H**, Kriegmair MC, Worst TS, Sikic D, Wach S, Taubert H, Wullich B, Weyerer V, Stoehr R, Zengerling F, Bolenz C, Breyer J, Burger M, Porubsky S, Hartmann A, Erben P, Eckstein M

Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Ann Oncol. 2019;30 5: 378

Weyerer VEJ, Stoehr R, **Juette H**, Wirtz R, Eckstein M, Roghmann F, Breyer J, Porubsky S, Sikic D, Bolenz C, Kriegmair MC, Hartmann A, Erben P

Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods

Ann Oncol. 2019;30 5: 380-380

Goertz O, Pieper A, Lauer H, **Stricker I**, Dadras M, Behr B, Lehnhardt M, Harati K

Long-term Outcome of 181 Patients With Liposarcomas of the Extremity and Truncal Wall.

Anticancer Res. 2019;39(10): 5747-5753

Rezniczek GA, Grunwald C, Hilal Z, Scheich J, Reifenberger G, **Tannapfel A**, Tempfer CB

ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).

Anticancer Res. 2019;39(3): 1267-1273

Tempfer CB, Dogan A, **Tischhoff I**, Hilal Z, Rezniczek GA

Chronic ectopic pregnancy: case report and systematic review of the literature.

Arch Gynecol Obstet. 2019;300(3): 651-660

Rajput Z, Hering KG, Kraus T, **Tannapfel A**, Sonnenschein G, Centmayer A, Radon K, Nowak D, Weinmann T  
Investigating the association between occupational exposure to asbestos and ovarian carcinoma: results from a pilot study in Germany.  
BMC Public Health. 2019;19(1): 1341

Hetze S, **van de Nes J**, Goerike S, Sarah D, Sure U, Oezkan N  
A 33-Year-Old Male with Five Years of Neck Pain.  
Brain Pathol. 2019;29(1): 141-142

Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Maghnouj A, Müller MP, Pohl M, Teschendorf C, Wolters H, Viebahn R, **Tannapfel A**, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D  
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in -Mutant Pancreatic and Colorectal Cancer.  
Cancer Res. 2019;79(9): 2367-2378

Villegas SL, Lederer B, Untch M, Holms F, Ulmer HU, Diebold K, Fasching PA, Weber K, Schmitt WD, Tesch H, Rezai M, Marme F, Sinn B, Hackmann J, Schneeweiss A, **Tannapfel A**, Nekljudova V, Denkert C, Loibl S  
Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials  
Cancer Res. 2019;79 S(4)

Svinarenko M, Katz SF, Tharehalli U, Mulaw MA, Maier HJ, Sunami Y, Fischer SK, Chen Y, Heurich S, Erkert L, **Tannapfel A**, Wirth T, Schirmbeck R, Seufferlein T, Lechel A  
An IKK/NF- $\kappa$ B Activation/p53 Deletion Sequence Drives Liver Carcinogenesis and Tumor Differentiation.  
Cancers (Basel). 2019;11(10)

### **Tannapfel A**

Pathologie  
Coloproctology. 2019;41(2): 92-92

### **Tannapfel A**

Lymph Node Ratio indicates Survival Time for Colon Carcinoma  
Coloproctology. 2019;41(2): 92-92

### **Tannapfel A**

Cystic Fibrosis is associated with Colon Cancer  
Coloproctology. 2019;41(5): 314-314

### **Tannapfel A**

Hot Topic: Pathologie  
Coloproctology. 2019;41(5): 314-314

Reinacher-Schick A, Hoffken N, Flott-Rahmel B, **Tannapfel A**  
Gender-specific differences in the management of colorectal cancer  
Der Gastroenterologe. 2019;14(2): 116-125

## **Tannapfel A**

Lymph Node Rate indicates Survival Time for Colon Carcinoma  
Der Gastroenterologe. 2019;14(2): 68-68

Meier JJ, Granhall C, Hoevelmann U, Andrea N, Plum-Moerschel L, Ramesh C, **Tannapfel A**, Kapitza C

Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes  
Diabetes. 2019;68 1

Israel H, Hartig A, Siebolts U, Wickenhauser C, **Tannapfel A**, Ernst F, Wahl U  
Persistent Diarrhea of an Elderly Lady - How to Combine Blood Pressure and Diarrhea  
Dtsch Med Wochenschr. 2019;144(6): 394-397

Bonella F, Campo I, Boerner E, Theegarten D, **Guzman J**, Costabel U  
Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in the management of patients with IPF  
Eur Respir J. 2019;54 63: -

Ohshimo S, Nishi H, Hosokawa K, Horimasu Y, Miyamoto S, Iwamoto H, Hamada H, Kawaguchi H, Bonella F, **Guzman J**, Costabel U, Hattori N, Shime N  
Imbalance in the oral bacterial flora as a risk factor for acute exacerbation in idiopathic pulmonary fibrosis  
Eur Respir J. 2019;54 63: 0A1926-

Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, **Tischhoff I**, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R  
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.  
Front Med (Lausanne). 2019;6: 295

Sivanathan V, Thomaidis T, Stahl M, Utz C, Maderer A, Lordick F, Mihaljevic A, Kanzler S, Hohler T, Thuss-Patience P, Moenig S, Kunzmann V, Schroll S, Ibach S, **Tannapfel A**, Meyer HJ, Schuhmacher C, Wilke HJ, Krause K, Karatas A, Galle PR, Moehler M  
PREDICTIVE SIGNIFICANCE OF ENDOSONOGRAPHIC (EUS) STAGING IN LOCALLY ADVANCED GASTRIC (GC) OR GASTROESOPHAGEAL-JUNCTION (AEG) ADENOCARCINOMA: ANALYSIS OF DATA FROM A PERIOPERATIVE AIO-CAO PHASE II STUDY  
Gastroenterology. 2019;156 1(6): S512-S513

Junk SV, Klein N, Schreek S, Zimmermann M, Möricke A, Bleckmann K, Alten J, **Dagdan E**, Cario G, Kratz CP, Schrappe M, Stanulla M  
TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.  
Haematologica. 2019;104(9): e402-e405

Köhler CU, Bonberg N, Ahrens M, Behrens T, Hovanec J, Eisenacher M, Noldus J, Deix T, Braun K, Gohlke H, Walter M, **Tannapfel A**, Tam Y, Sommerer F, Marcus K, Jöckel KH, Erbel R, Cantor CR, Käfferlein HU, Brüning T  
Noninvasive diagnosis of urothelial cancer in urine using DNA hypermethylation signatures-

Gender matters.

Int J Cancer. 2019;145(10): 2861-2872

Lang K, Kahveci S, Bonberg N, Wichert K, Behrens T, Hovanec J, Roghmann F, Noldus J, Tam YC, **Tannapfel A**, Käfferlein HU, Brüning T

TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.

Int J Mol Sci. 2019;20(18)

Förster S, **Tannapfel A**

Use of monoclonal antibodies in pathological diagnostics

Internist (Berl). 2019;60(10): 1021-1031

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Kohno N, Komoto D, Awai K, Shime N, Bonella F, **Guzman J**, Kühl H, Costabel U, Hattori N

Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study.

J Clin Med. 2019;8(12)

Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, **Tannapfel A**, Reinacher-Schick AC, Geissler M  
FOLFIRI Plus Panitumumab As First-Line Treatment of Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).

J Clin Oncol. 2019;37(35): 3401-3411

Geissler M, Riera-Knorrenschild J, Martens UM, Held S, Greeve J, Florschütz A, Ettrich TJ, Kanzler S, **Tannapfel A**, Heinemann V, Reinacher-Schick AC, Seufferlein T, Wessendorf S, Modest DP

Final results and OS of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFIRI plus panitumumab versus FOLFIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).

J Clin Oncol. 2019;37 S(15)

Modest DP, Nörenberg D, Seidensticker M, Ricke J, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich TJ, Kanzler S, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, **Tannapfel A**, Reinacher-Schick AC, Geissler M

Tumor dynamics with fluorouracil/leucovorin, irinotecan, and oxaliplatin (FOLFIRI) plus panitumumab (pmab) or FOLFIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI-A randomized, op

J Clin Oncol. 2019;37 S(15)

Uhl W, Ettrich TJ, Reinacher-Schick AC, Algul H, Friess H, Kornmann M, Koenig A, Ghadimi M, Wittel UA, Gallmeier E, Wille K, Geissler M, Schimanski CC, Prasnikar N, **Tannapfel A**, Perkhofer L, Berger AW, Seufferlein T

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)- Safety interim analysis

J Clin Oncol. 2019;37 S(15)

Ettrich TJ, Berger AW, Schwerdel D, Reinacher-Schick AC, Uhl W, Alguel H, Friess H, Koenig A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, **Tannapfel A**, Kleger A, Seufferlein T

A blood-based assay for diagnosis of early-stage pancreatic cancer.

J Clin Oncol. 2019;37 S(4)

Luu AM, Meurer K, Herzog T, **Munding J**, Uhl W, Braumann C

Surprising Twist in the Plot - Sister Mary Joseph's Nodule of Pancreatic Cancer Mimicking Wound Infection after Umbilical Hernia Repair.

J Gastrointest Cancer. 2019;50(1): 113-115

Höhn P, Braumann C, Munding J, **Tannapfel A**, Uhl W, Künzli BM

Outcome Determining Factors of Intraductal Papillary Neoplasm of the Biliary Tract (IPNB)-a Single Center Survey and Analysis of Current Literature.

J Gastrointest Cancer. 2019;50(1): 160-169

Fahlbusch T, Künzli B, Schlottmann R, **Tannapfel A**, Uhl W, Braumann C

Tuberculosis Mimicking Disseminated Peritoneal Carcinomatosis of a Sigmoid Carcinoma.

J Gastrointest Surg. 2019;23(4): 877-878

Carolus AE, Möller J, Hofmann MR, **van de Nes JAP**, Welp H, Schmieder K, Brenke C

Comparison between optical coherence tomography imaging and histological sections of peripheral nerves.

J Neurosurg. 2019;: 1-8

Simidjiiska-Belyaeva M, Belyaev O, Lehnhardt M, Harati K, **Stricker I**, Nicolas V, Daigeler A  
Use of a self-contained vacuum-assisted biopsy system in the assessment of soft tissue tumors.

J Surg Oncol. 2019;120(4): 740-745

Gambichler T, Kröger ES, **Tannapfel A**, Dörler M, Susok L

Hypereosinophilic syndrome complicated by severe vascular damage and gangrene.

J Vasc Surg Cases Innov Tech. 2019;5(3): 384-387

Barth A, Nassenstein I, Tröbs RB, **Tannapfel A**, Dercks H, Rostásy K, Wegener-Panzer A  
N-Methyl-D-Aspartate Receptor Encephalitis with Psychiatric Symptoms and an Ovarian Teratoma Detected by MRI in a 17-Year-Old Girl.

Neuropediatrics. 2019;50(4): 253-256

Hauptelshofer S, Leichsenring T, Berg S, Pedreiturria X, Joachim SC, **Tischhoff I**, Otte JM, Bopp T, Fantini MC, Esser C, Willbold D, Gold R, Faissner S, Kleiter I

Smad7 in intestinal CD4 T cells determines autoimmunity in a spontaneous model of multiple sclerosis.

Proc Natl Acad Sci U S A. 2019;116(51): 25860-25869

Lyu Y, Boerner E, Theegarten D, **Guzman J**, Kreuter M, Costabel U, Bonella F

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia.

Respiration. 2019;98(1): 29-37

Brechmann T, Günther K, Neid M, **Tannapfel A**, Schmiegel W

Phenotype of histologically suspected drug-induced colitis; results of a comparative,



retrospective cohort study.

Scand J Gastroenterol. 2019;54(7): 855-862

**Benz S, Tannapfel A**, Tam Y, Grünenwald A, Vollmer S, Stricker I

Proposal of a new classification system for complete mesocolic excision in right-sided colon cancer.

Tech Coloproctol. 2019;23(3): 251-257

Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, **Tannapfel A**, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.

Theranostics. 2019;9(5): 1280-1287

Dietrich CF, **Tannapfel A**, Jang HJ, Kim TK, Burns PN, Dong Y

Ultrasound Imaging of Hepatocellular Adenoma Using the New Histology Classification.

Ultrasound Med Biol. 2019;45(1): 1-10

Weyerer V, Eckstein M, Comperat E, **Juette H**, Allory Y, Stoehr R, Wullich B, Roupret M, Hartmann A, Bertz S

Large nested variant of urothelial carcinoma: a prime example of a FGFR3-mutated, luminal tumour

Virchows Arch. 2019;475 1: S188-S188

**Tannapfel A**, Reinacher-Schick A

Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?

Visc Med. 2019;35(1): 1-2

**Tannapfel A**, Reinacher-Schick A, Hacker U, Lorenzen S, Möhler M, Vogel A

Immunotherapy: New Options in Gastrointestinal Cancers?

Visc Med. 2019;35(1): 47-51

Luu AM, Hoehn P, Vogel SR, Reinacher-Schick A, **Munding J**, Uhl W, Braumann C

Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer.

Visc Med. 2019;35(6): 387-391

Brechmann T, Günther K, Neid M, Schmiegel W, **Tannapfel A**

Triggers of histologically suspected drug-induced colitis.

World J Gastroenterol. 2019;25(8): 967-979

Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Höcht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Mönig S, Ott K, Quante M, Röcken C, Schlattmann P, Schmiegel WH, Schreyer A, **Tannapfel A**, Thuss-Patience P, Weimann A, Unverzagt S

S3-Leitlinie Magenkarzinom - Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs - Langversion 2.0 - August 2019. AWMF-Registernummer: 032/009OL.

Z Gastroenterol. 2019;57(12): 1517-1632

Gerbes AL, ...Straub BK, **Tannapfel A**, Trowe E, van Leeuwen P, Werner J, Wettstein M, Wörns MA

[Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)].

Z Gastroenterol. 2019;57(5): 611-680

Bonella F, Sennekamp J, Joest M, Rolke M, Ohshimo S, **Guzman J**, Taube C, Costabel U  
Clinical Relevance of Antinuclear Antibodies (ANA) in Patients with Hypersensitivity  
Pneumonitis (HP): A Single Centre Experience

Am J Respir Crit Care Med. 2018;197: -

Geissler M, Klingler T, Riera-Knorrenschild J, **Tannapfel A**, Seufferlein T, Held S,  
Florschütz A, Kanzler S, Heinemann V, Reinacher-Schick A, Martens U  
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with  
RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the  
AIO (AIO-KRK0109)

Ann Oncol. 2018;29 5

Berger AW, Ettrich TJ, Schwerdel D, Reinacher-Schick A, Algul H, König AO, Gallmeier E,  
Wille K, Daum S, Geissler M, **Tannapfel A**, Uhl W, Seufferlein T

A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal  
adenocarcinoma

Ann Oncol. 2018;29 8

Geissler M, Klingler T, Knorrenschild JR, **Tannapfel A**, Greeve J, Seufferlein T, Kanzler S,  
Held S, Heinemann V, Reinacher-Schick A, Martens UM

1st-line mFOLFOXIRI plus panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A  
randomized phase II VOLFI trial of the AIO (KRK-0109)

Ann Oncol. 2018;29 8: -

Reinacher-Schick A, Juette H, Noepel-Duenebacke S, Arnold D, Basara N, Boehner H,  
Dahm T, Feder I, Herzog T, Hiller W, Mueller L, Engel L, Senkal M, Teschendorf C, Trenn G,  
Verdoodt B, Wolters H, Uhl W, **Tannapfel A**

Microsatellite instability is associated with distinct clinical and molecular characteristics in  
early colon cancer: Analysis of a molecular registry of the AIO colorectal study group -

Colopredict Plus

Ann Oncol. 2018;29 8: 174-174

Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler  
M, Algül H, Gallmeier E, Atzpodiën J, Kornmann M, Muche R, Prasnikar N, **Tannapfel A**,  
Reinacher-Schick A, Uhl W, Seufferlein T

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable  
pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized,  
controlled, phase II study of the AIO pancreatic cancer group.

BMC Cancer. 2018;18(1): 1298

Tempfer CB, **Tischhoff I**, Dogan A, Hilal Z, Schultheis B, Kern P, Reznicek GA

Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

BMC Cancer. 2018;18(1): 530

Diaz-Carballo D, Saka S, Klein J, Rennkamp T, Acikelli AH, Malak S, Jastrow H, Wennemuth G, Tempfer CB, Schmitz I, **Tannapfel A**, Strumberg D  
A Distinct Oncogenerative Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity.  
Cancer Res. 2018;78(9): 2318-2331

Maslehaty H, **Van de Nes J**, Teuber-Hanselmann S, Moenninghoff C, Sure U, Oezkan N  
Never Too Old? Occurrence of Medulloblastoma in the Elderly beyond the 70th Year of Life.  
Case Rep Neurol Med. 2018;2018: 8639404

Carolus A, Schroers R, **Tischhoff I**, Schmieder K, Brenke C  
Rare finding in peripheral nerve surgery: an unicentric Castleman disease presenting as median nerve tumour.  
Case Reports Plast Surg Hand Surg. 2018;5(1): 68-71

Tautenhahn HM, Brückner S, Rauchfuß F, Donndorf F, Ardelt M, Fahrner R, **Tannapfel A**, Settmacher U  
[Precancerous and early stage cancer of the bile duct system].  
Chirurg. 2018;89(4): 274-280

Griewank KG, Koelsche C, **van de Nes JAP**, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D  
Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.  
Clin Cancer Res. 2018;24(18): 4494-4504

Noepel-Duenebecke S, Arnold D, Hertel J, **Tannapfel A**, Hinke A, Hegewisch-Becker S, Reinacher-Schick A  
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.  
Clin Colorectal Cancer. 2018;17(4): e733-e739

Rösch T, Altenhofen L, Kretschmann J, Hagen B, Brenner H, Pox C, Schmiegel W, Theilmeier A, Aschenbeck J, **Tannapfel A**, von Stillfried D, Zimmermann-Fraedrich K, Wegscheider K  
Risk of Malignancy in Adenomas Detected During Screening Colonoscopy.  
Clin Gastroenterol Hepatol. 2018;16(11): 1754-1761

### **Tannapfel A**

Meta-analysis on mesocolic Excision - complete versus non-complete  
Coloproctology. 2018;40(2): 98-98

Zaun G, Schuler M, Herrmann K, **Tannapfel A**  
CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.  
Deutsches Ärzteblatt international. 2018;115(10): 157-162

Hegewisch-Becker S, Nöpel-Dünnebecke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, **Tannapfel A**, Arnold D  
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic

factors from the AIO KRK0207 first-line and maintenance therapy trial.  
Eur J Cancer. 2018;101: 105-113

Stahl M, Maderer A, Lordick F, Mihaljevic AL, Kanzler S, Hoehler T, Thuss-Patience P, Mönig S, Kunzmann V, Schroll S, Sandermann A, **Tannapfel A**, Meyer HJ, Schuhmacher C, Wilke H, Moehler M, Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CA Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/ Eur J Cancer. 2018;93: 119-126

Ohshimo S, Kida Y, Kyo M, Horimasu Y, Miyamoto S, Iwamoto H, Hamada H, Hattori N, Bonella F, **Guzman J**, Costabel U, Shime N  
Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis  
Eur Respir J. 2018;52 62: -

Weber L, Maßberg D, Becker C, Altmüller J, Ubrig B, Bonatz G, Wölk G, Philippou S, **Tannapfel A**, Hatt H, Gisselmann G  
Olfactory Receptors as Biomarkers in Human Breast Carcinoma Tissues.  
Front Oncol. 2018;8: 33

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, **Tannapfel A**, Jutte H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A  
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients- Analysis of the Phase III AIO KRK-0207 Trial.  
Front Oncol. 2018;8: 474

Weber L, Schulz WA, Philippou S, Eckardt J, Ubrig B, Hoffmann MJ, **Tannapfel A**, Kalbe B, Gisselmann G, Hatt H  
Characterization of the Olfactory Receptor OR10H1 in Human Urinary Bladder Cancer.  
Front Physiol. 2018;9: 456

Langhorst J, Li Y, Schroder D, Dobos G, Jutte H, **Tannapfel A**, Umutlu L  
SIMULTANEOUS PET/MRI ENTEROGRAPHY WITH 18F-FDG PET/MRI IN PREDICTING HISTOLOGICAL HEALING IN ULCERATIVE COLITIS: A PROSPECTIVE SEGMENT-BASED STUDY USING THE RILEY AND THE NANCY INDEX  
Gastroenterology. 2018;154 1(6): S1069-S1069

Langhorst J, Schroder D, Koch AK, Dobos G, Boone JH, Rueffer A, Jutte H, **Tannapfel A**  
MONITORING HISTOLOGICAL ACTIVITY IN ULCERATIVE COLITIS CORRELATION OF FECAL BIOMARKERS WITH THE RILEY SCORE AND THE NANCY INDEX  
Gastroenterology. 2018;154 1(6): S595-S595

Feder IS, Theile A, **Tannapfel A**  
Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany.  
Int J Occup Med Environ Health. 2018;31(3): 293-305

Feder IS, Theile A, **Tannapfel A**

Authors' response (March 14, 2018) to the letter to the Editor concerning the paper "Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany".  
Int J Occup Med Environ Health. 2018;31(6): 841-843

Feder IS, Theile A, **Tannapfel A**

Authors' response (April 30, 2018) to the letter to the editor concerning the paper "Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany".  
Int J Occup Med Environ Health. 2018;31(6): 849-851

Sivanathan V, Stahl M, Utz C, Maderer A, Lordick F, Mihaljevic A, Kanzler S, Hohler T, Thuss-Patience P, Monig S, Kunzmann V, Schroll S, Sandermann A, **Tannapfel A**, Meyer HJ, Schuhmacher C, Wilke HJ, Krause K, Mohler M  
Predictive Significance of endosonographic (EUS) Staging in locally advanced gastric Adenocarcinoma of the Stomach (MC) or esophagogastric Junction (AEG)-Analysis of Data from a perioperative AIO-CAO Phase II Study  
Internist (Berl). 2018;59 1: S43-S44

Krauss SD, Yosef HK, Lechtonen T, Jutte H, **Tannapfel A**, Kafferlein HU, Bruning T, Roghmann F, Noldus J, El-Mashtoly SF, Gerwert K, Mosig A  
Integrating spatial, morphological, and textural information for improved cell type differentiation using Raman microscopy  
J Chemom. 2018;32(1): e2973-

Armacki M, Trugenberger AK, Ellwanger AK, Eiseler T, Schwerdt C, Bettac L, Langgartner D, Azoitei N, Halbgebauer R, Groß R, Barth T, Lechel A, Walter BM, Kraus JM, Wiegrefe C, Grimm J, Scheffold A, Schneider MR, Peuker K, Zeißig S, Britsch S, Rose-John S, Vettorazzi S, Wolf E, **Tannapfel A**, Steinestel K, Reber SO, Walther P, Kestler HA, Radermacher P, Barth TF, Huber-Lang M, Kleger A, Seufferlein T  
Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure.  
J Clin Invest. 2018;128(11): 5056-5072

Siveke JT, Lueong S, Hinke A, Herbst A, **Tannapfel A**, Reinacher-Schick AC  
Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial.  
J Clin Oncol. 2018;36 S(15)

Geissler M, Riera-Knorrenschild J, **Tannapfel A**, Greeve J, Florschütz A, Wessendorf S  
mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).  
J Clin Oncol. 2018;36 S(15)

Langhorst J, Schroeder D, Koch A, Boone J, Rueffer A, Jütte H, **Tannapfel A**  
Monitoring histological activity in ulcerative colitis: correlation of faecal biomarkers with the Riley Score and the Nancy Index  
J Crohns Colitis. 2018;12 1: S200-S200

Luu AM, Herzog T, Hoehn P, **Reinacher-Schick A**, Munding J, Uhl W, Braumann C  
FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.

J Gastrointest Oncol. 2018;9(2): E9-E12

Svinarenko M, Sarah-Fee K, Maier H, Sunami Y, **Tannapfel A**, Seufferlein T, Lechel A  
Inflammation driven hepatocarcinogenesis is associated with a progenitor-like phenotype and Trp53 dependent differentiation

J Hepatol. 2018;68 1: S666-S666

Justinger C, Gruden J, Kouladouros K, Stravodimos C, Reimer P, **Tannapfel A**, Binnenhei M, Bentz M, Tatsch K, Rüdiger T, Schön MR

Histopathological changes resulting from selective internal radiotherapy (SIRT).

J Surg Oncol. 2018;117(5): 1084-1091

Guo Y, Shao C, Blau T, **Tannapfel A**, Koch KR, Heindl LM

Ocular Metastasis of Bronchial Typical Carcinoid.

J Thorac Oncol. 2018;13(9): 1422-1423

Gotzmann M, Grabbe S, Schöne D, von Frieling-Salewsky M, Dos Remedios CG, Strauch J, Bechtel M, Dietrich JW, **Tannapfel A**, Mügge A, Linke WA

Alterations in Titin Properties and Myocardial Fibrosis Correlate With Clinical Phenotypes in Hemodynamic Subgroups of Severe Aortic Stenosis.

Journal of the American College of Cardiology. Basic to translational science. 2018;3(3): 335-346

Leichsenring T, Haupteltshofer S, **Tannapfel A**, Gold R, Kleiter I

Characterisation of pro- and antiinflammatory mechanisms in the gut mucosa of patients with multiple sclerosis

Mult Scler. 2018;24 2: 186-186

Knappe UJ, Tischoff I, **Tannapfel A**, Reinbold WD, Möller I, Sucker A, Schadendorf D, Griewank KG, van de Nes JAP

Intraventricular melanocytoma diagnosis confirmed by gene mutation profile.

Neuropathology. 2018;38(3): 288-292

Harati K, Kolbensschlag J, Bohm J, Niggemann H, Joneidi-Jafari H, **Stricker I**, Lehnhardt M, Daigeler A

Long-term outcomes of patients with soft tissue sarcoma of the chest wall: Analysis of the prognostic significance of microscopic margins.

Oncol Lett. 2018;15(2): 2179-2187

Weyhe D, Uslar V, Sahlmann B, **Tannapfel A**

Circumferential Resection Margin influences long term survival after pancreatic adenocarcinoma

Oncol Res Treat. 2018;41 1: 171-171

Moehler M, Maderer A, Lordick F, **Tannapfel A**, Kanzler S, Hoehler T, Thuss-Patience P, Monig S, Meyer HJ, Wilke H, Stahl MK

Perioperative chemotherapy plus +/- EGFR inhibition in unselected patients with locally advanced esophagogastric cancer: a randomized phase II study with a large advanced

biomarker program of the German Cancer Society (AIO/CAO STO-0801)  
Oncol Res Treat. 2018;41 1: 69-69

Geissler M, Klingler T, **Tannapfel A**, Riera-Knorrenschild J, Held S, Greeve J, Wessendorf S, Seufferlein T, Kanzler S, Heinemann V, Reinacher-Schick A, Martens U  
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): an update of the randomized phase II VOLFI trial of the AIO (AIO-KRK0109)  
Oncol Res Treat. 2018;41 4: 120-120

Feder IS, Jülich M, **Tannapfel A**, Tischoff I  
[The German Mesothelioma Register : Current pathological diagnostics and services].  
Pathologe. 2018;39(Suppl 2): 241-246

### **Tannapfel A**

[Meeting of the Gastroenteropathology Working Group on 24 May 2018 : 102nd annual conference of the German Society of Pathology in Berlin].  
Pathologe. 2018;39(Suppl 2): 322-323

Papadopoulos S, Vidovic G, **Neid M**, Abdallah A  
Using Fat Grafting to Treat Breast Implant Capsular Contracture.  
Plast Reconstr Surg Glob Open. 2018;6(11): e1969

Kuepper C, Kallenbach-Thieltges A, Juette H, **Tannapfel A**, Großerueschkamp F, Gerwert K  
Quantum Cascade Laser-Based Infrared Microscopy for Label-Free and Automated Cancer Classification in Tissue Sections.  
Scientific Reports. 2018;8(1): 7717

Bauschke A, Altendorf-Hofmann A, Katenkamp K, Mireskandari M, Rauchfuss F, Tautenhahn M, Theis B, **Tannapfel A**, Settmacher U  
BILE DUCT DAMAGE AFTER COLD STORAGE OF DECEASED DONOR AND LIVING DONORS LIVERS AFTER LIVER TRANSPLANTATION  
Transpl Int. 2018;31 5: 16-16

Fahlbusch T, **Tannapfel A**, Uhl W, Braumann C  
Acinar Cell Cystadenoma - a Rarity in Advanced von Hippel-Lindau Disease: A Case Report.  
Visc Med. 2018;34(1): 73-75